

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057676 A1

(51) International Patent Classification⁷: C07D 237/22,
409/12, 405/12, 417/12, 403/12, A61K 31/501, A61P
35/00

(74) Agent: JEANETTE, Henry, C.; Schering-Plough Corpo-
ration, Patent Department, 2000 Galloping Hill Road, Ke-
nilworth, NJ 07033-0530 (US).

(21) International Application Number: PCT/US03/00299

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ,
DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV,
MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT,
RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UZ, VC, VN, YU, ZA, ZM.

(22) International Filing Date: 3 January 2003 (03.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/346,248 4 January 2002 (04.01.2002) US
10/335,789 2 January 2003 (02.01.2003) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants: SCHERING CORPORATION [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530
(US). PHARMACOPEIA, INC. [US/US]; 3000 Eastpark
Boulevard, Cranbury, NJ 08512 (US).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

(72) Inventors: TAVERAS, Arthur, G.; 3 Headley Court,
Denville, NJ 07834 (US). DWYER, Michael; 235
Katherine Street, Scotch Plains, NJ 07076 (US). CHAO,
Jianping; 23 Brainerd Road, Summit, NJ 07901 (US).
BALDWIN, John, J.; 621 Gypsy Hill Circle, Gwynedd
Valley, PA 19437 (US). MERRITT, Robert, J.; 14
Gloucester Lane, Ewing, NJ 08618 (US). LI, Ge; 815
Taolin Road, Building 7, Room 201, LuJiaZui Garden,
LuJiaZui, 200135 Shanghai (CN). CHAO, Jianhua; 93
Lakeview Court, Pompton Lakes, NJ 07442 (US). YU,
Younong; 251-B Rutgers Road, Piscataway, NJ 08854
(US).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 03/057676 A1

(54) Title: 3,4-DI-SUBSTITUTED PYRIDAZINEDIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS



(I)

(57) Abstract: Disclosed compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

**3,4 -Di-SUBSTITUTED PYRIDAZINEDIONES
AS CXC CHEMOKINE RECEPTOR ANTAGONISTS**

5

FIELD OF THE INVENTION

10 This invention relates to novel substituted pyridazinedione compounds, pharmaceutical compositions containing the compounds, and the use of the compounds in treating CXC chemokine-mediated diseases.

BACKGROUND OF THE INVENTION

15 Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T-cells, eosinophils, basophils, neutrophils and endothelial cells to sites of inflammation and tumor growth. There are two main classes of chemokines, the CXC-chemokines and the CC- chemokines. The class depends on whether the first two cysteines are separated by a single amino acid
20 (CXC-chemokines) or are adjacent (CC-chemokines). The CXC-chemokines include interleukin-8 (IL-8), neutrophil-activating protein-1 (NAP-1), neutrophil-activating protein-2 (NAP-2), GRO α , GRO β , GRO γ , ENA-78, GCP-2, IP-10, MIG and PF4. CC chemokines include RANTES, MIP -1 α , MIP-2 β , monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3 and eotaxin. Individual members
25 of the chemokine families are known to be bound by at least one chemokine receptor, with CXC-chemokines generally bound by members of the CXCR class of receptors, and CC-chemokines by members of the CCR class of receptors. For example, IL-8 is bound by the CXCR-1 and CXCR-2 receptors.

30 Since CXC-chemokines promote the accumulation and activation of neutrophils, these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis. Baggiolini et al., FEBS Lett. 307, 97 (1992); Miller et al., Crit. Rev. Immunol. 12, 17

(1992); Oppenheim et al., Annu. Rev. Immunol. 9, 617 (1991); Seitz et al., J. Clin. Invest. 87, 463 (1991); Miller et al., Am. Rev. Respir. Dis. 146, 427 (1992); Donnely et al., Lancet 341, 643 (1993).

ELRCXC chemokines including IL-8, GRO α , GRO β , GRO γ , NAP-2, and
5 ENA-78 (Strieter et al. 1995 JBC 270 p. 27348-57) have also been implicated in the induction of tumor angiogenesis (new blood vessel growth). All of these chemokines are believed to exert their actions by binding to the 7 transmembrane G-protein coupled receptor CXCR2 (also known as IL-8RB), while IL-8 also binds CXCR1 (also known as IL-8RA). Thus, their angiogenic activity is due to their
10 binding to and activation of CXCR2, and possible CXCR1 for IL-8, expressed on the surface of vascular endothelial cells (ECs) in surrounding vessels.

Many different types of tumors have been shown to produce ELRCXC chemokines and their production has been correlated with a more aggressive phenotype (Inoue et al. 2000 Clin Cancer Res 6 p. 2104-2119) and poor prognosis
15 (Yoneda et al. 1998 J Nat Cancer Inst 90 p. 447-454). Chemokines are potent chemotactic factors and the ELRCXC chemokines have been shown to induce EC chemotaxis. Thus, these chemokines probably induce chemotaxis of endothelial cells toward their site of production in the tumor. This may be a critical step in the induction of angiogenesis by the tumor. Inhibitors of CXCR2 or dual inhibitors of
20 CXCR2 and CXCR1 will inhibit the angiogenic activity of the ELRCXC chemokines and therefore block the growth of the tumor. This anti-tumor activity has been demonstrated for antibodies to IL-8 (Arenberg et al. 1996 J Clin Invest 97 p. 2792-2802), ENA-78 (Arenberg et al. 1998 J Clin Invest 102 p. 465-72), and GRO α (Haghnegahdar et al. J. Leukoc Biology 2000 67 p. 53-62).

25 Many tumor cells have also been shown to express CXCR2 and thus tumor cells may also stimulate their own growth when they secrete ELRCXC chemokines. Thus, along with decreasing angiogenesis, inhibitors of CXCR2 may directly inhibit the growth of tumor cells.


Hence, the CXC-chemokine receptors represent promising targets for the
30 development of novel anti-inflammatory and anti-tumor agents.

There remains a need for compounds that are capable of modulating activity at CXC-chemokine receptors. For example, conditions associated with an increase in IL-8 production (which is responsible for chemotaxis of neutrophil and T-cell

subsets into the inflammatory site and growth of tumors) would benefit by compounds that are inhibitors of IL-8 receptor binding.

Summary of the Invention

The invention provides novel compounds represented by the formula (I):



(I)

pharmaceutically acceptable salts, solvates, isomers or prodrugs thereof, wherein:

R^1 and R^{15} are the same or different and each is independently selected

10 from the group consisting of:

- a) H,
- b) aryl,
- c) heteroaryl,
- d) alkyl,
- 15 e) arylalkyl,
- f) heteroarylalkyl,
- g) cycloalkyl,
- h) heterocycloalkyl,
- i) cycloalkylalkyl and
- 20 j) heterocycloalkylalkyl,

wherein said aryl, heteroaryl, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, and heterocycloalkylalkyl groups are optionally substituted with one or more substituents selected from the group consisting of:


- a) halogen,
- 25 b) CF_3 ,
- c) COR^{13} ,
- d) OH,
- e) $NR^{13}R^{14}$,
- f) NO_2 ,

5

10





















- g) cyano,
- h) $\text{SO}_2\text{OR}^{13}$,
- i) $-\text{Si}(\text{alkyl})$,
- j) $-\text{Si}(\text{aryl})$
- k) CO_2R^{13}
- l) $\text{CONR}^{13}\text{R}^{14}$,
- m) $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
- n) SO_2R^{13} ,
- o) $-\text{OR}^{13}$,
- p) $-\text{O}(\text{C}=\text{O})\text{R}^{13}$,
- q) $-\text{O}(\text{C}=\text{O})\text{NR}^{13}\text{R}^{14}$,
- r) $-\text{NR}^{13}\text{COR}^{14}$, and
- s) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$;










A is selected from the group consisting of:

















15


5








and



;

B is selected from the group consisting of:



wherein:

R^2 is selected from the group consisting of:


- 5 a) hydrogen,
 b) OH,
 c) C(O)OH,
 d) SH,
 e) $SO_2NR^{13}R^{14}$,
 f) $NHC(O)R^{13}$,
 g) $NHSO_2NR^{13}R^{14}$,
10 h) $NR^{13}R^{14}$,
 i) $NHSO_2R^{13}$,
 j) $C(O)NR^{13}R^{14}$,
 k) $C(O)NHOR^{13}$,
 l) $C(O)NR^{13}OH$,
15 m) $OC(O)R^{13}$ and
 n) an optionally substituted heterocyclic acidic functional group,
with the proviso that if R^2 is $SO_2NR^{13}R^{14}$, then at least one of R^{13} and R^{14} must be
hydrogen;

20 R^3 and R^4 are the same or different and each is independently selected from
the group consisting of:

- a) hydrogen,
 b) halogen,
 c) alkyl,
 d) alkoxy,
25 e) OH,
 f) CF_3 ,
 g) OCF_3 ,
 h) NO_2 ,
 i) $C(O)R^{13}$,
30 j) $C(O)OR^{13}$,
 k) $C(O)NR^{13}R^{14}$,
 l) $SO_{(t)}NR^{13}R^{14}$,
 m) $SO_{(t)}R^{13}$,

n) $C(O)NR^{13}OR^{14}$,

o)



p) cyano,

5 q) aryl and

r) heteroaryl,

wherein said aryl or heteroaryl group is optionally substituted with one or more R^9 group;

10 R^5 and R^6 are the same or different and each is independently selected from the group consisting of

a) hydrogen,

b) halogen,

c) alkyl,

d) alkoxy,

15 e) CF_3 ,

f) OCF_3 ,

g) NO_2 ,

h) $C(O)R^{13}$,

i) $C(O)OR^{13}$,

20 j) $C(O)NR^{13}R^{14}$,

k) $SO_{(t)}NR^{13}R^{14}$,

l) $C(O)NR^{13}OR^{14}$,

m) cyano,

n) aryl and

25 o) heteroaryl,

wherein said aryl or heteroaryl group is optionally substituted with one or more R^9 group;

R^7 and R^8 are the same or different and each is independently selected from the group consisting of

30 a) H,

- 5 b) alkyl,
 c) aryl,
 d) heteroaryl,
 e) arylalkyl,
 f) heteroarylalkyl,
 g) cycloalkyl,
 h) cycloalkylalkyl,
 i) CO_2R^{13} ,
 j) $\text{CONR}^{13}\text{R}^{14}$,
10 k) fluoroalkyl,
 l) alkynyl,
 m) alkenyl,
 n) alkynylalkyl,
 o) alkenylalkyl and
15 p) cycloalkenyl,


wherein said alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, fluoroalkyl, alkynyl, alkenyl, alkynylalkyl, alkenylalkyl, and cycloalkenyl groups are optionally substituted with one or more substituents selected from the group consisting of:

- 20 a) halogen,
 b) CF_3 ,
 c) COR^{13} ,
 d) OH,
 e) $\text{NR}^{13}\text{R}^{14}$,
25 f) NO_2 ,
 g) cyano,
 h) $\text{SO}_2\text{OR}^{13}$,
 i) $-\text{Si}(\text{alkyl})$,
 j) $-\text{Si}(\text{aryl})$,
30 k) $(\text{R}^{13})_2\text{R}^{14}\text{Si}$,
 l) CO_2R^{13} ,
 m) $\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$,
 n) $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,

- o) SO_2R^{13} ,
 p) $-\text{OR}^{13}$,
 q) $-\text{O}(\text{C}=\text{O})\text{R}^{13}$,
 r) $-\text{O}(\text{C}=\text{O})\text{NR}^{13}\text{R}^{14}$,
 s) $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$ and
 t) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$;

R^9 is selected from the group consisting of:

- a) R^{13} ;
 b) halogen;
 c) $-\text{CF}_3$;
 d) $-\text{COR}^{13}$;
 e) $-\text{OR}^{13}$;
 f) $-\text{NR}^{13}\text{R}^{14}$;
 g) $-\text{NO}_2$;
 h) cyano;
 i) $-\text{SO}_2\text{R}^{13}$;
 j) $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$;
 k) $-\text{NR}^{13}\text{COR}^{14}$;
 l) $-\text{CONR}^{13}\text{R}^{14}$;
 m) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$;
 n) CO_2R^{13} , and
 o)



R^{10} and R^{11} are the same or different and each is independently selected

from the group consisting of:

- a) hydrogen,
 b) halogen,
 c) CF_3 ,
 d) OCF_3 ,
 e) $\text{NR}^{13}\text{R}^{14}$,
 f) $\text{NR}^{13}\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$,

- 5 g) OH,
h) C(O)OR¹³,
i) SH,
j) SO_(t)NR¹³R¹⁴,
k) SO₂R¹³,
l) NHC(O)R¹³,
m) N⁻HSO₂N⁻R¹³R¹⁴,
n) N⁻HSO₂R¹³,
10 o) C(O)NR¹³R¹⁴,
p) C(O)NR¹³OR¹⁴,
q) OC(O)R¹³ and
r) cyano;

R¹² is selected from the group consisting of:

- 15 a) hydrogen,
b) OC(O)R¹³,
c) aryl,
d) heteroaryl,
e) arylalkyl,
f) cycloalkyl,
20 g) alkyl,
h) cycloalkylalkyl and
i) heteroarylalkyl,

wherein said aryl, heteroaryl, arylalkyl, cycloalkyl, alkyl, cycloalkylalkyl and heteroarylalkyl group are optionally substituted with one or more R⁹ group;

25 R¹³ and R¹⁴ are the same or different and each is independently selected from the group consisting of:

- 30 a) H,
b) alkyl,
c) aryl,
d) heteroaryl,
e) arylalkyl,
f) heteroarylalkyl,
g) cycloalkyl,

h) cycloalkylalkyl and

i) fluoroalkyl,

wherein said alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, and fluoroalkyl group are optionally substituted with one or more

5 substituents selected from the group consisting of:

a) alkyl,

b) aryl,

c) arylalkyl,

d) fluoroalkyl,

10 e) cycloalkyl,

f) cycloalkylalkyl,

g) heteroaryl,

h) heteroarylalkyl,

i) amino,

15 j) carbonyl and

k) halogen; or

R^{13} and R^{14} when taken together with the atoms to which they are attached form a 3 to 7 membered heterocyclic ring, wherein when the ring formed is a 6 or 7 membered heterocyclic ring said ring optionally contains one to two additional
20 heteroatoms independently selected from the group consisting of O, S and N, and wherein said heterocyclic ring is optionally substituted with one or more substituents selected from the group consisting of:

a) alkyl,

b) aryl,

25 c) arylalkyl,

d) fluoroalkyl,

e) cycloalkyl,

f) cycloalkylalkyl,

g) heteroaryl,

30 h) heteroarylalkyl,

i) amino,

j) carbonyl and

k) halogen;

n is 0-6;
m is 1-5;
p is 0-4 and
t is 1 or 2.

5 Another aspect of the invention is a pharmaceutical composition comprising the compound of formula (I) in combination or association with a pharmaceutically acceptable carrier or diluent.

Another aspect of the invention is a method of treating an α -chemokine mediated disease in a patient (e.g., a mammal such as a human being) in need of
10 such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Another aspect of the invention is a method of treating a chemokine-mediated disease in a patient in need of such treatment, wherein the chemokine
15 binds to a CXCR2 and/or CXCR1 receptor in said patient (e.g., a mammal, such as a human being), said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Another aspect of the invention is a method of treating a chemokine-mediated disease in a patient in need of said treatment wherein the chemokine
20 binds to a CXC receptor in said patient (e.g., a mammal, such as a human being), said method comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

25 Examples of chemokine mediated diseases include psoriasis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis or
30 thrombosis, alzheimer's disease, graft vs. host reaction, allograft rejections and malaria. Angiogenic ocular disease (e.g., ocular inflammation (e.g., Uveitis), retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet

type preferred and corneal neovascularization) is another example of a chemokine mediated diseases

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and administering a therapeutically effective amount of at least one known anti-cancer agent and/or radiation therapy.

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and administering a therapeutically effective amount of at least one known anti-cancer agent and/or radiation therapy, wherein said anti-cancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids (including synthetic analogs), and synthetics.

Another aspect of the invention is a method of inhibiting angiogenesis in a patient in need of such inhibition comprising administering to said patient an angiogenesis-inhibiting amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Another aspect of the invention is a method of inhibiting angiogenesis in a patient in need of such inhibition comprising administering to said patient an angiogenesis-inhibiting amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and administering at least one known anti-angiogenesis compound.

Another aspect of the invention is a method of inhibiting angiogenesis in a patient in need of such inhibition comprising administering to said patient an angiogenesis-inhibiting amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and administering at least one known anti-angiogenesis compound, wherein said anti-angiogenesis compound is

selected from the group consisting of Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, VEGF receptor kinase inhibitors, docetaxel (e.g., Taxotere), and paclitaxel (e.g., Taxol).

Another aspect of the invention is a method of treating a disease in a patient in need of such treatment, said disease selected from the group consisting of gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi's sarcoma associated virus and atherosclerosis comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Another aspect of the invention is a method of treating an angiogenic ocular disease in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Another aspect of the invention is a method of treating an angiogenic ocular disease in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein said angiogenic ocular disease is selected from the group consisting of ocular inflammation (e.g., Uveitis), retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization.

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and wherein said cancer being treated is selected from the group consisting of melanoma, gastric carcinoma or non-small cell lung carcinoma.

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and administering at least one known anti-cancer agent and/or radiation therapy, and wherein said cancer being treated is selected from

the group consisting of melanoma, gastric carcinoma or non-small cell lung carcinoma.

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and administering at least one known anti-cancer agent and/or radiation therapy, wherein said cancer being treated is selected from the group consisting of melanoma, gastric carcinoma or non-small cell lung carcinoma, and wherein said anti-cancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids (including synthetic analogs), and synthetics.

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and administering at least one known anti-cancer agent and/or radiation therapy, wherein said cancer being treated is selected from the group consisting of melanoma, gastric carcinoma or non-small cell lung carcinoma, wherein said anti-cancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids (including synthetic analogs), and synthetics, and wherein said anti-angiogenic agent is selected from the group consisting of Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, VEGF receptor kinase inhibitors, docetaxel (e.g., Taxotere), and paclitaxel (e.g., Taxol).

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient concurrently or sequentially, a therapeutically effective amount of (a) a compound of formula (I) and (b) a microtubule affecting agent or antineoplastic agent or anti-angiogenesis agent or VEGF receptor kinase inhibitor or antibodies against the VEGF receptor or interferon, and/or c) radiation.

Another aspect of the invention is a method of treating cancer in a patient in need of such treatment comprising administering to said patient, concurrently or sequentially, an effective amount of (a) a compound of formula (I) and (b) a microtubule affecting agent (*e.g.*, paclitaxel).

5

Detailed Description

Unless indicated otherwise, the following definitions apply throughout the present specification and claims. These definitions apply regardless of whether a term is used by itself or in combination with other terms. Hence the definition of
10 "alkyl" applies to "alkyl" as well as to the "alkyl" portions of "alkoxy", etc.

When any variable (*e.g.*, aryl, R^2) occurs more than one time in any constituent, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

15 Alkyl represents a straight or branched saturated hydrocarbon chain having the designated number of carbon atoms. Where the number of carbon atoms is not specified, 1 to 20 carbons are intended.

The term halogen or halo is intended to include fluorine, chlorine, bromine or iodine.

20 The term fluoroalkyl represents a straight or branched saturated hydrocarbon chain having the designated number of carbon atoms, substituted with one or more fluorine atoms. Where the number of carbon atoms is not specified, 1 to 20 carbons are intended.

Aryl represents a carbocyclic group having from 6 to 14 carbon atoms and
25 having at least one benzenoid ring, with all available substitutable aromatic carbon atoms of the carbocyclic group being intended as possible points of attachment. Examples include, but are not limited to, phenyl, naphthyl, indenyl, tetrahydronaphthyl, indanyl, anthracenyl, fluorenyl and the like. The aryl group can be substituted with one, two, or three substituents independently selected from
30 lower alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, sulfhydryl, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl.

aralkyl – represents a moiety containing an aryl group linked via a lower alkyl;

alkylaryl – represents a moiety containing a lower alkyl linked via an aryl group;

5 cycloalkyl – represents a saturated carbocyclic ring having from 3 to 8 carbon atoms, preferably 5 or 6, which can be substituted.

The term heterocycle or heterocyclic ring is defined by all non-aromatic, heterocyclic rings of 3-7 atoms containing 1-3 heteroatoms selected from N, O and S, such as oxirane, oxetane, tetrahydrofuran, tetrahydropyran, pyrrolidine,
10 piperidine, piperazine, tetrahydropyridine, tetrahydropyrimidine, tetrahydrothiophene, tetrahydrothiopyran, morpholine, hydantoin, valerolactam, pyrrolidinone, and the like.

The term heterocyclic acidic functional group is intended to include groups such as, pyrrole, imidazole, triazole, tetrazole, and the like. Such groups can be
15 unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of lower alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, sulfhydryl, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl.

Heteroaryl refers to 5- or 10-membered single or benzofused aromatic rings
20 consisting of 1 to 3 heteroatoms independently selected from the group consisting of -O-, -S, and -N=, provided that the rings do not possess adjacent oxygen and/or sulfur atoms. The heteroaryl group can be substituted with one, two, or three substituents independently selected from lower alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, sulfhydryl, amino, alkylamino
25 and dialkylamino.

N-oxides can form on a tertiary nitrogen present in an R substituent, or on =N- in a heteroaryl ring substituent and are included in the compounds of formula (I).

Also included in the invention are tautomers, enantiomers and other optical
30 isomers of compounds of Formula I, as well as pharmaceutically acceptable salts and solvates thereof.

The term "prodrug," as used herein, represents compounds which are rapidly transformed *in vivo* to the parent compound of the above formula, for

example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.


As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

Examples of "one or more", as used herein, include (a) 1, 2 or 3, (b) 1 or 2, and (c) 1.

Examples of "at least one", as used herein, include (a) 1, 2 or 3, (b) 1 or 2, and (c) 1.

The following terms may be referred to herein by the abbreviations indicated: tetrahydrofuran (THF), ethanol (EtOH), methanol (MeOH), acetic acid (HOAc or AcOH), ethyl acetate (EtOAc), N,N-dimethylformamide (DMF), trifluoroacetic acid (TFA), trifluoroacetic anhydride (TFAA), 1-hydroxybenzotriazole (HOBT), m-chloroperbenzoic acid (MCPBA), triethylamine (Et₃N), diethyl ether (Et₂O), ethyl chloroformate (ClCO₂Et), 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (DEC), N,N'-dicyclohexylcarbodiimide (DCC), sodium hydroxide (NaOH), magnesium sulfate (MgSO₄), dichloromethane (CH₂Cl₂), ammonium hydroxide (NH₄OH), sodium sulfate (Na₂SO₄), thin layer chromatography (TLC).

In a preferred group of compounds of formula (I), A is selected from the group consisting of



wherein,

- R^7 and R^8 are the same or different and each is independently selected from
- 5 the group consisting of
- a) H,
 - b) alkyl,
 - c) aryl,

- 5
- d) heteroaryl,
 - e) arylalkyl,
 - f) heteroarylalkyl,
 - g) cycloalkyl,
 - h) cycloalkylalkyl,
 - i) CO_2R^{13} ,
 - j) $\text{CONR}^{13}\text{R}^{14}$,
 - k) fluoroalkyl,
 - l) alkynyl,
 - 10 m) alkenyl,
 - n) alkynylalkyl,
 - o) alkenylalkyl and
 - p) cycloalkenyl,

15 wherein said alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, fluoroalkyl, alkynyl, alkenyl, alkynylalkyl, alkenylalkyl, and cycloalkenyl groups are optionally substituted with one or more substituents selected from the group consisting of:

- 20
- a) cyano;
 - b) CO_2R^{13} ;
 - c) $\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$;
 - d) $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
 - e) NO_2 ;
 - f) CF_3 ;
 - g) $-\text{OR}^{13}$;
 - 25 h) $-\text{NR}^{13}\text{R}^{14}$;
 - i) $-\text{O}(\text{C}=\text{O})\text{R}^{13}$;
 - j) $-\text{O}(\text{C}=\text{O})\text{NR}^{13}\text{R}^{14}$, and
 - k) halogen;


R^9 is selected from the group consisting of:

- 30
- a) R^{13} ,
 - b) halogen,
 - c) $-\text{CF}_3$,
 - d) $-\text{COR}^{13}$,

5


- e) $-OR^{13}$,
- f) $-NR^{13}R^{14}$,
- g) $-NO_2$,
- h) cyano,
- i) $-SO_2R^{13}$,
- j) $-SO_2NR^{13}R^{14}$,
- k) $-NR^{13}COR^{14}$,
- l) $-CONR^{13}R^{14}$,
- m) $-NR^{13}CO_2R^{14}$,
- n) CO_2R^{13} and

10



B is selected from the group consisting of:

25



wherein,

R^2 is selected from the group consisting of:

- a) hydrogen,
- b) OH,
- c) C(O)OH,
- d) SH,
- e) $SO_2NR^{13}R^{14}$,
- f) $NHC(O)R^{13}$,
- g) $NHSO_2NR^{13}R^{14}$,
- h) $NR^{13}R^{14}$,
- i) $NHSO_2R^{13}$,
- j) $C(O)NR^{13}R^{14}$,
- k) $C(O)NHOR^{13}$,

l) $C(O)NR^{13}OH$,

m) $OC(O)R^{13}$ and

n) an optionally substituted heterocyclic acidic functional group, with the proviso that if R^2 is $SO_2NR^{13}R^{14}$, at least one of R^{13} and R^{14} must be hydrogen;

R^3 and R^4 are the same or different and each is independently selected from the group consisting of:

a) hydrogen,

b) halogen,

c) alkyl,

d) alkoxy,

e) OH,

f) CF_3 ,

g) OCF_3 ,

h) NO_2 ,

i) $C(O)R^{13}$,

j) $C(O)OR^{13}$,


k) $C(O)NR^{13}R^{14}$,

l) $SO_{(t)}NR^{13}R^{14}$,

m) $SO_{(t)}R^{13}$,

n) $C(O)NR^{13}OR^{14}$,

o)



p) cyano,

q) aryl and

r) heteroaryl,

wherein said aryl or heteroaryl group is optionally substituted with one or more R^9 group;

R^5 and R^6 are the same or different and each is independently selected from the group consisting of:

- 5 a) hydrogen,
b) halogen,
c) alkyl,
d) alkoxy,
e) CF_3 ,
f) OCF_3 ,
g) NO_2 ,
h) $\text{C}(\text{O})\text{R}^{13}$,
i) $\text{C}(\text{O})\text{OR}^{13}$,
10 j) $\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$,
k) $\text{SO}_{(t)}\text{NR}^{13}\text{R}^{14}$,
l) $\text{C}(\text{O})\text{NR}^{13}\text{OR}^{14}$,
m) cyano,
n) aryl and
15 o) heteroaryl,

wherein said aryl or heteroaryl group is optionally substituted with one or more R^9 group;

R^{10} and R^{11} are the same or different and each is independently selected from the group consisting of:

- 20 a) hydrogen,
b) halogen,
c) CF_3 ,
d) OCF_3 ,
e) $\text{NR}^{13}\text{R}^{14}$,
25 f) $\text{NR}^{13}\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$,
g) OH ,
h) $\text{C}(\text{O})\text{OR}^{13}$,
i) SH ,
j) $\text{SO}_{(t)}\text{NR}^{13}\text{R}^{14}$,
30 k) SO_2R^{13} ,
l) $\text{NHC}(\text{O})\text{R}^{13}$,
m) $\text{NHSO}_2\text{NR}^{13}\text{R}^{14}$,
n) $\text{NHSO}_2\text{R}^{13}$,

- o) $C(O)NR^{13}R^{14}$,
- p) $C(O)NR^{13}OR^{14}$,
- q) $OC(O)R^{13}$ and
- r) cyano;

5 R^{12} is selected from the group consisting of:

- a) hydrogen,
- b) $OC(O)R^{13}$,
- c) aryl,
- d) heteroaryl,
- 10 e) arylalkyl,
- f) cycloalkyl,
- g) alkyl,
- h) cycloalkylalkyl and
- i) heteroarylalkyl

15 wherein said aryl, heteroaryl, arylalkyl, cycloalkyl, alkyl, cycloalkylalkyl or heteroarylalkyl group is optionally substituted with one or more R^9 group;

R^{13} and R^{14} are the same or different and each is independently selected from the group consisting of:

- a) H;
- 20 b) alkyl,
- c) aryl,
- d) heteroaryl,
- e) arylalkyl,
- f) heteroarylalkyl,
- 25 g) cycloalkyl,
- h) cycloalkylalkyl and
- i) fluoroalkyl,

wherein said alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, and fluoroalkyl groups are optionally substituted with one or more

30 substituents selected from the group consisting of:

- a) alkyl,
- b) aryl,
- c) arylalkyl,

- 5 d) fluoroalkyl,
e) cycloalkyl,
f) cycloalkylalkyl,
g) heteroaryl,
h) heteroarylalkyl,
i) amino,
j) carbonyl and
k) halogen or

10 R^{13} and R^{14} when taken together with the atoms to which they are attached
can form a 3 to 7 membered heterocyclic ring wherein when the ring formed is a 6
or 7 membered heterocyclic ring, said ring optionally contains one to two additional
heteroatoms independently selected from the group consisting of O, S and N and
wherein said heterocyclic ring can be substituted with one or more substituents
selected from the group consisting of:

- 15 a) alkyl,
b) aryl,
c) arylalkyl,
d) fluoroalkyl,
e) cycloalkyl,
20 f) cycloalkylalkyl,
g) heteroaryl,
h) heteroarylalkyl,
i) amino,
j) carbonyl and
25 k) halogen;

n is 0-6;


m is 1-5;

p is 0-4 and

t is 1 or 2.

30 Preferably, R^1 and R^{15} are the same or different and are individually selected
from the group consisting of H, methyl, aryl and cyclohexyl.

More preferably, A is selected from the group consisting of:




wherein,

R⁷ and R⁸ are the same or different and each is independently selected from the group consisting of H, alkyl, fluoroalkyl such as, CF₃ and CF₂CH₃, cycloalkyl and cycloalkylalkyl, such as, for example, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, cyclopropylmethyl and cyclohexyl and

R^9 is selected from the group consisting of H, halogen (e.g. bromine, fluorine or chlorine), CH_3 , CF_3 , fluoroalkyl, cyano, $-OCH_3$, and NO_2 .

More preferably, B is selected from the group consisting of:



5 wherein

R^2 is selected from the group consisting of H, OH, $NHC(O)R^{13}$ and $NHSO_2R^{13}$;

R^3 is selected from the group consisting of $SO_2NR^{13}R^{14}$, NO_2 , cyano, $C(O)NR^{13}R^{14}$, SO_2R^{13} ; and $C(O)OR^{13}$;

10 R^4 is selected from the group consisting of H, NO_2 , halo, cyano, CH_3 and CF_3 ;

R^5 is selected from the group consisting of H, CF_3 , NO_2 , halo and cyano;

R^6 is selected from the group consisting of H, alkyl and CF_3 ;

15 R^{10} and R^{11} are the same or different and each is independently selected from the group consisting of:

- a) hydrogen,
- b) halo,
- c) CF_3 ,
- d) OCF_3 ,
- 20 e) $NR^{13}R^{14}$,
- f) $NR^{13}C(O)NR^{13}R^{14}$,
- g) OH,
- h) $C(O)OR^{13}$,
- i) SH,

- 5 j) $\text{SO}_{(1)}\text{NR}^{13}\text{R}^{14}$,
k) SO_2R^{13} ,
l) $\text{NHC(O)}\text{R}^{13}$,
m) $\text{NHSO}_2\text{NR}^{13}\text{R}^{14}$,
n) $\text{NHSO}_2\text{R}^{13}$,
o) $\text{C(O)}\text{NR}^{13}\text{R}^{14}$,
p) $\text{C(O)}\text{NR}^{13}\text{OR}^{14}$,
q) $\text{OC(O)}\text{R}^{13}$,
r) COR^{13} ,
10 s) OR^{13} and
t) cyano;


R^{12} is selected from the group consisting of hydrogen and $\text{C(O)}\text{OR}^{13}$;

R^{13} and R^{14} are the same or different and each is independently selected from the group consisting of methyl, ethyl and isopropyl; or

- 15 R^{13} and R^{14} when taken together with the atoms to which they are attached can form a 3 to 7 membered heterocyclic ring wherein when the ring formed is a 6 or 7 membered heterocyclic ring, said ring optionally contains one to two additional heteroatoms independently selected from the group consisting of O, S and N and wherein said heterocyclic ring can be substituted with one or more substituents
20 selected from the group consisting of:

- a) alkyl,
b) aryl,
c) arylalkyl,
d) fluoroalkyl,
25 e) cycloalkyl,
f) cycloalkylalkyl,
g) heteroaryl,
h) heteroarylalkyl,
i) amino,
30 j) carbonyl and
k) halogen.

Even more preferably, A is selected from:



wherein,


R^7 is selected from the group consisting of H, CF_3 , fluoroalkyl, alkyl and cycloalkyl;

5 R^8 is selected from the group consisting of H, alkyl and fluoroalkyl;

R^9 is selected from the group consisting of H, F, Cl, Br, CF_3 , alkyl and fluoroalkyl.

Still even more preferably, A is selected from the group consisting of:

34




wherein,

R^7 is selected from the group consisting of H, CF_3 , CF_2CH_3 , methyl, ethyl, isopropyl, cyclopropyl and t-butyl;

5 R^8 is H;

R^9 is selected from the group consisting of H, F, Cl, Br, CF_3 , alkyl and fluoroalkyl; and

B is:



10 wherein:

R^2 is selected from the group consisting of H, OH, $NHC(O)R^{13}$ and $NHSO_2R^{13}$;

R^3 is selected from the group consisting of $SO_2NR^{13}R^{14}$, NO_2 , cyano, $C(O)NR^{13}R^{14}$, SO_2R^{13} ; and $C(O)OR^{13}$;

15 R^4 is selected from the group consisting of H, NO_2 , halo, cyano, CH_3 and CF_3 ;

R^5 is selected from the group consisting of H, CF_3 , NO_2 , halo and cyano;

R^6 is selected from the group consisting of H, alkyl and CF_3 ; and

R^{13} and R^{14} are the same or different and each is independently selected
20 from the group consisting of methyl, ethyl and isopropyl; or


R^{13} and R^{14} when taken together with the atoms to which they are attached can form a 3 to 7 membered heterocyclic ring wherein when the ring formed is a 6 or 7 membered heterocyclic ring, said ring optionally contains one to two additional heteroatoms independently selected from the group consisting of O, S and N and

wherein said heterocyclic ring can be substituted with one or more substituents selected from the group consisting of:


- 5
- a) alkyl,
 - b) aryl,
 - c) arylalkyl,
 - d) fluoroalkyl,
 - e) cycloalkyl,
 - f) cycloalkylalkyl,
 - g) heteroaryl,
 - 10 h) heteroarylalkyl,
 - i) amino,
 - j) carbonyl and
 - k) halogen.

Yet even still more preferred,

- 15 A is selected from the group consisting of:



and B is:



wherein:

- 20 R^2 is selected from the group consisting of H, OH, NHC(O)R^{13} and $\text{NHSO}_2\text{R}^{13}$;

R^3 is selected from the group consisting of $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, $\text{C(O)NR}^{13}\text{R}^{14}$, SO_2R^{13} , NO_2 or cyano;

R^4 is selected from the group consisting of H, NO_2 , CF_3 , CH_3 , halo and cyano,

R^5 is selected from the group consisting of H, halo, NO_2 , cyano and CF_3 ;

5 R^6 is selected from the group consisting of H, CF_3 and alkyl;

R^7 is selected from the group consisting of H, CF_3 , CF_2CH_3 , methyl, ethyl, isopropyl, cyclopropyl and t-butyl;


R^8 is H;

10 R^9 is selected from the group consisting of H, F, Cl, Br, CF_3 , alkyl, and fluoroalkyl; and


R^{13} and R^{14} are each independently selected from the group consisting of methyl and ethyl.

Most preferably,

A is selected from the group consisting of:



and B is



wherein,

5

R² is -OH;

R³ is CONR¹³R¹⁴;

R⁴ is selected from the group consisting of H, CH₃, halo and CF₃;









R⁵ is selected from the group consisting of H and cyano;









R⁶ is selected from the group consisting of H, CH₃ and CF₃; and









10

R¹³ and R¹⁴ are each methyl.









Representative compounds of the invention are listed below:
















Preferred compounds of the invention are listed below:














More preferred compounds of the invention are listed below:





For compounds of the invention having at least one asymmetrical carbon atom, all isomers, including diastereomers, enantiomers and rotational isomers are contemplated as being part of this invention. The invention includes *d* and *l*

isomers in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, or by separating isomers of a compound of formula (I).

Compounds of formula (I) can exist in unsolvated and solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for purposes of this invention.

A compound of formula (I) may form pharmaceutically acceptable salts with organic and inorganic acids or bases. Examples of suitable bases for salt formation include but are not limited to sodium hydroxide, lithium hydroxide, potassium hydroxide, and calcium hydroxide. Salts of phenols can be made by heating acidic compounds with any of the above mentioned bases according to procedures well known to those skilled in the art. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution, such as dilute aqueous sodium hydroxide, lithium hydroxide, potassium hydroxide, calcium hydroxide, potassium carbonate, ammonia or sodium bicarbonate. The neutral forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their respective neutral forms for purposes of the invention.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A.

Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g., nitrogen.

Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal composition can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

The compounds of the invention may also be delivered by direct application to the tumor site following surgery, e.g., in a sponge preparation.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.01 mg to about 1000 mg, preferably from about 0.01 mg to about 750 mg, more preferably from about 0.01 mg to about 500 mg, and most preferably from about 0.01 mg to about 250 mg, according to the particular application.

The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For

convenience, the total dosage may be divided and administered in portions during the day as required.

The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as
5 age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 0.04 mg/day to about 4000 mg/day, in two to four divided doses.

Another aspect of the invention is a method for treating cancer, comprising
10 administering to a patient in need thereof, concurrently or sequentially, a therapeutically effective amount of (a) a compound of formula (I) and (b) a chemotherapeutic agent (i.e. an antineoplastic agent, microtubule affecting agent or anti-angiogenesis agent).

In a preferred embodiment, a compound of formula (I) is combined with one
15 of the following antineoplastic agents: gemcitabine, paclitaxel (Taxol®), 5-Fluorouracil (5-FU), cyclophosphamide (Cytosan®), temozolomide, taxotere or Vincristine.

Classes of compounds that can be used as the chemotherapeutic agent (antineoplastic agent) include: alkylating agents, antimetabolites, natural products
20 and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids (including synthetic analogs), and synthetics. Examples of compounds within these classes are given below.

Alkylating agents (including nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes): Uracil mustard, Chloromethine,
25 Cyclophosphamide (Cytosan®), Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylene-melamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, and Temozolomide.

Antimetabolites (including folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors): Methotrexate, 5-Fluorouracil,
30 Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, and Gemcitabine.

Natural products and their derivatives (including vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins): Vinblastine,

Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, paclitaxel (paclitaxel is commercially available as Taxol® and is described in more detail below in the subsection entitled "Microtubule Affecting Agents"), Mithramycin, Deoxyco-formycin, Mitomycin-C, L-Asparaginase,
5 Interferons (especially IFN- α), Etoposide, and Teniposide.

Hormones and steroids (including synthetic analogs): 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Tamoxifen, Methylprednisolone, Methyl-testosterone, Prednisolone, Triamcinolone, Chlorotrianisene,
10 Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Zoladex.

Synthetics (including inorganic complexes such as platinum coordination complexes): Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, and Hexamethylmelamine.

15 Anti-angiogenic agents include Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, taxotere and Taxol.

20 Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR), e.g., 1996 edition (Medical Economics
25 Company, Montvale, NJ 07645-1742, USA); the disclosure of which is incorporated herein by reference thereto.

As used herein, a microtubule affecting agent is a compound that interferes with cellular mitosis, *i.e.*, having an anti-mitotic effect, by affecting microtubule formation and/or action. Such agents can be, for instance, microtubule stabilizing
30 agents or agents which disrupt microtubule formation.

Microtubule affecting agents useful in the invention are well known to those of skill in the art and include, but are not limited to allocolchicine (NSC 406042), Halichondrin B (NSC 609395), colchicine (NSC 757), colchicine derivatives (*e.g.*,

NSC 33410), dolastatin 10 (NSC 376128), maytansine (NSC 153858), rhizoxin (NSC 332598), paclitaxel (Taxol[®], NSC 125973), Taxol[®] derivatives (e.g., derivatives (e.g., NSC 608832), thiocolchicine (NSC 361792), trityl cysteine (NSC 83265), vinblastine sulfate (NSC 49842), vincristine sulfate (NSC 67574),
5 epothilone A, epothilone, and discodermolide (see Service, (1996) *Science*, 274:2009) estramustine, nocodazole, MAP4, and the like. Examples of such agents are also described in the scientific and patent literature, see, e.g., Bulinski (1997) *J. Cell Sci.* 110:3055-3064; Panda (1997) *Proc. Natl. Acad. Sci. USA* 94:10560-10564; Muhlradt (1997) *Cancer Res.* 57:3344-3346; Nicolaou (1997)
10 *Nature* 387:268-272; Vasquez (1997) *Mol. Biol. Cell.* 8:973-985; Panda (1996) *J. Biol. Chem.* 271:29807-29812.

Particularly preferred agents are compounds with paclitaxel-like activity. These include, but are not limited to paclitaxel and paclitaxel derivatives (paclitaxel-like compounds) and analogues. Paclitaxel and its derivatives are available
15 commercially. In addition, methods of making paclitaxel and paclitaxel derivatives and analogues are well known to those of skill in the art (see, e.g., U.S. Patent Nos: 5,569,729; 5,565,478; 5,530,020; 5,527,924; 5,508,447; 5,489,589; 5,488,116; 5,484,809; 5,478,854; 5,478,736; 5,475,120; 5,468,769; 5,461,169; 5,440,057; 5,422,364; 5,411,984; 5,405,972; and 5,296,506).

20 More specifically, the term "paclitaxel" as used herein refers to the drug commercially available as Taxol[®] (NSC number: 125973). Taxol[®] inhibits eukaryotic cell replication by enhancing polymerization of tubulin moieties into stabilized microtubule bundles that are unable to reorganize into the proper structures for mitosis. Of the many available chemotherapeutic drugs, paclitaxel
25 has generated interest because of its efficacy in clinical trials against drug-refractory tumors, including ovarian and mammary gland tumors (Hawkins (1992) *Oncology*, 6: 17-23, Horwitz (1992) *Trends Pharmacol. Sci.* 13: 134-146, Rowinsky (1990) *J. Natl. Canc. Inst.* 82: 1247-1259).

Additional microtubule affecting agents can be assessed using one of many
30 such assays known in the art, e.g., a semiautomated assay which measures the tubulin-polymerizing activity of paclitaxel analogs in combination with a cellular assay to measure the potential of these compounds to block cells in mitosis (see Lopes (1997) *Cancer Chemother. Pharmacol.* 41:37-47).

Generally, activity of a test compound is determined by contacting a cell with that compound and determining whether or not the cell cycle is disrupted, in particular, through the inhibition of a mitotic event. Such inhibition may be mediated by disruption of the mitotic apparatus, e.g., disruption of normal spindle formation. Cells in which mitosis is interrupted may be characterized by altered morphology (e.g., microtubule compaction, increased chromosome number, etc.).

In a preferred embodiment, compounds with possible tubulin polymerization activity are screened *in vitro*. In a preferred embodiment, the compounds are screened against cultured WR21 cells (derived from line 69-2 wap-ras mice) for inhibition of proliferation and/or for altered cellular morphology, in particular for microtubule compaction. *In vivo* screening of positive-testing compounds can then be performed using nude mice bearing the WR21 tumor cells. Detailed protocols for this screening method are described by Porter (1995) *Lab. Anim. Sci.*, 45(2):145-150.

Other methods of screening compounds for desired activity are well known to those of skill in the art. Typically such assays involve assays for inhibition of microtubule assembly and/or disassembly. Assays for microtubule assembly are described, for example, by Gaskin *et al.* (1974) *J. Molec. Biol.*, 89: 737-758. U.S. Patent No. 5,569,720 also provides *in vitro* and *in vivo* assays for compounds with paclitaxel-like activity.

Methods for the safe and effective administration of the above-mentioned microtubule affecting agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR), e.g., 1996 edition (Medical Economics Company, Montvale, NJ 07645-1742, USA); the disclosure of which is incorporated herein by reference thereto.

The amount and frequency of administration of the compounds of formula (I) and the chemotherapeutic agents and/or radiation therapy will be regulated according to the judgment of the attending clinician (physician) considering such factors as age, condition and size of the patient as well as severity of the disease being treated. A dosage regimen of the compound of formula (I) can be oral administration of from 10 mg to 2000 mg/day, preferably 10 to 1000 mg/day, more

preferably 50 to 600 mg/day, in two to four (preferably two) divided doses, to block tumor growth. Intermittent therapy (e.g., one week out of three weeks or three out of four weeks) may also be used.

The chemotherapeutic agent and/or radiation therapy can be administered according to therapeutic protocols well known in the art. It will be apparent to those skilled in the art that the administration of the chemotherapeutic agent and/or radiation therapy can be varied depending on the disease being treated and the known effects of the chemotherapeutic agent and/or radiation therapy on that disease. Also, in accordance with the knowledge of the skilled clinician, the therapeutic protocols (e.g., dosage amounts and times of administration) can be varied in view of the observed effects of the administered therapeutic agents (i.e., antineoplastic agent or radiation) on the patient, and in view of the observed responses of the disease to the administered therapeutic agents.

In the methods of this invention, a compound of formula (I) is administered concurrently or sequentially with a chemotherapeutic agent and/or radiation. Thus, it is not necessary that, for example, the chemotherapeutic agent and the compound of formula (I), or the radiation and the compound of formula (I), should be administered simultaneously or essentially simultaneously. The advantage of a simultaneous or essentially simultaneous administration is well within the determination of the skilled clinician.

Also, in general, the compound of formula (I) and the chemotherapeutic agent do not have to be administered in the same pharmaceutical composition, and may, because of different physical and chemical characteristics, have to be administered by different routes. For example, the compound of formula (I) may be administered orally to generate and maintain good blood levels thereof, while the chemotherapeutic agent may be administered intravenously. The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician. The initial administration can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.

The particular choice of a compound of formula (I), and chemotherapeutic agent and/or radiation will depend upon the diagnosis of the attending physicians

and their judgement of the condition of the patient and the appropriate treatment protocol.

5 The compound of formula (I), and chemotherapeutic agent and/or radiation may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the proliferative disease, the condition of the patient, and the actual choice of chemotherapeutic agent and/or radiation to be administered in conjunction (i.e., within a single treatment protocol) with the compound of formula (I).

10 If the compound of formula (I) and the chemotherapeutic agent and/or radiation are not administered simultaneously or essentially simultaneously, then the initial order of administration of the compound of formula (I) and the chemotherapeutic agent and/or radiation, may not be important. Thus, the compound of formula (I) may be administered first followed by the administration of the chemotherapeutic agent and/or radiation; or the chemotherapeutic agent and/or radiation may be administered first followed by the administration of the compound of formula (I). This alternate administration may be repeated during a single treatment protocol. The determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment protocol, is well within the knowledge of the skilled physician after evaluation of the disease being treated and the condition of the patient. For example, the chemotherapeutic agent and/or radiation may be administered first, especially if it is a cytotoxic agent, and then the treatment continued with the administration of a compound of formula (I) followed, where determined advantageous, by the administration of the chemotherapeutic agent and/or radiation, and so on until the treatment protocol is complete.

Thus, in accordance with experience and knowledge, the practicing physician can modify each protocol for the administration of a component (therapeutic agent--i.e., the compound of formula (I), chemotherapeutic agent or radiation) of the treatment according to the individual patient's needs, as the treatment proceeds.

30 The attending clinician, in judging whether treatment is effective at the dosage administered, will consider the general well-being of the patient as well as more definite signs such as relief of disease-related symptoms, inhibition of tumor growth, actual shrinkage of the tumor, or inhibition of metastasis. Size of the tumor

can be measured by standard methods such as radio-logical studies, e.g., CAT or MRI scan, and successive measurements can be used to judge whether or not growth of the tumor has been retarded or even reversed. Relief of disease-related symptoms such as pain, and improvement in overall condition can also be used to help judge effectiveness of treatment.

BIOLOGICAL EXAMPLES

The compounds of the present invention are useful in the treatment of CXC-chemokine mediated conditions and diseases. This utility is manifested in their ability to inhibit IL-8 and GRO- α chemokine which may be demonstrated by the following *in vitro* assays.

Receptor Binding Assays:

CXCR1 SPA Assay

For each well of a 96 well plate, a reaction mixture of 10 μ g hCXCR1-CHO overexpressing membranes (Biosignal) and 200 μ g/well WGA-SPA beads (Amersham) in 100 μ l is prepared in CXCR1 assay buffer (25 mM HEPES, pH 7.8, 2 mM CaCl_2 , 1mM MgCl_2 , 125 mM NaCl, 0.1% BSA) (Sigma). A 0.4 nM stock of ligand, [^{125}I]-IL-8 (NEN) is prepared in the CXCR1 assay buffer. 20X stock solutions of test compounds are prepared in DMSO (Sigma). A 6 X stock solution of IL-8 (R&D) is prepared in CXCR2 assay buffer. The above solutions are added to a 96-well assay plate (PerkinElmer) as follows: 10 μ l test compound or DMSO, 40 μ l CXCR1 assay buffer or IL-8 stock, 100 μ l of reaction mixture, 50 μ l of ligand stock (Final [Ligand] = 0.1 nM). The assay plates are shaken for 5 minutes on plate shaker, then incubated for 8 hours before cpm/well are determined in Microbeta Trilux counter (PerkinElmer). % Inhibition of Total binding-NSB (250 nM IL-8) is determined for IC50 values.

CXCR2 SPA Assay

For each well of a 96 well plate, a reaction mixture of 4 μ g hCXCR2-CHO overexpressing membranes (Biosignal) and 200 μ g/well WGA-SPA beads (Amersham) in 100 μ l is prepared in CXCR2 assay buffer (25 mM HEPES, pH 7.4, 2 mM CaCl_2 , 1mM MgCl_2). A 0.4 nM stock of ligand, [^{125}I]-IL-8 (NEN), is prepared in the CXCR2 assay buffer. 20X stock solutions of test compounds are prepared

in DMSO (Sigma). A 6 X stock solution of GRO- α (R&D) is prepared in CXCR2 assay buffer. The above solutions are added to a 96-well assay plate (PerkinElmer or Corning) as follows: 10 μ l test compound or DMSO, 40 μ l CXCR2 assay buffer or GRO- α stock, 100 μ l of reaction mixture, 50 μ l of ligand stock (Final [Ligand] = 0.1 nM). When 40 X stock solutions of test compounds in DMSO are prepared, then the above protocol is used except instead 5 μ l test compound or DMSO and 45 μ l CXCR2 assay buffer are used. The assay plates are shaken for 5 minutes on a plate shaker, then incubated for 2-8 hours before cpm/well are determined in Microbeta Trilux counter (PerkinElmer). % Inhibition of total binding minus non-specific binding (250 nM Gro- α or 50 μ M antagonist) is determined and IC50 values calculated.

Calcium Fluorescence Assay (FLIPR)

HEK 293 cells stably transfected with hCXCR2 and G α i/q are plated at 10,000 cells per well in a Poly-D-Lysine Black/Clear plate (Becton Dickinson) and incubated 48 hours at 5% CO₂, 37°C. The cultures are then incubated with 4 mM fluo-4, AM (Molecular Probes) in Dye Loading Buffer (1% FBS, HBSS w. Ca & Mg, 20 mM HEPES (Cellgro), Probenicid (Sigma)) for 1 hour. The cultures are washed with wash buffer (HBSS w Ca, & Mg, 20 mM HEPES, Probenicid (2.5 mM)) three times, then 100 μ l/well wash buffer is added.

During incubation, compounds are prepared as 4X stocks in 0.4% DMSO (Sigma) and wash buffer and added to their respective wells in the first addition plate. IL-8 or GRO- α (R&D Systems) concentrations are prepared 4X in wash buffer + 0.1% BSA and added to their respective wells in second addition plate.

Culture plate and both addition plates are then placed in the FLIPR imaging system to determine change in calcium fluorescence upon addition of compound and then ligand. Briefly, 50 μ l of compound solutions or DMSO solution is added to respective wells and change in calcium fluorescence measured by the FLIPR for 1 minute. After a 3 minute incubation within the instrument, 50 μ l of ligand is then added and the change in calcium fluorescence measured by the FLIPR instrument for 1 minute. The area under each stimulation curve is determined and the values are used to determine % Stimulation by compound (agonist) and % Inhibition of

Total Calcium response to ligand (0.3 nM IL-8 or GRO- α) for IC50 values of the test compounds.

Chemotaxis assays for 293-CXCR2

A chemotaxis assay is setup using Fluoroblok inserts (Falcon) for 293-CXCR2 cells (HEK-293 cells overexpressing human CXCR2). The standard protocol used at present is as follows:

1. Inserts are coated with collagenIV (2ug/ml) for 2 hrs at 37°C.
2. The collagen is removed and inserts are allowed to air dry overnight.
3. Cells are labeled with 10uM calcein AM (Molecular Probes) for 2 hrs.
- 10 Labeling is done in complete media with 2% FBS.
4. Dilutions of compound are made in minimal media (0.1% BSA) and placed inside the insert which is positioned inside the well of a 24 well plate. Within the well is IL-8 at a concentration of 0.25nM in minimal media. Cells are washed and resuspended in minimal media and placed inside the insert at a concentration
- 15 of 50,000 cells per insert.
5. Plate is incubated for 2hrs and inserts are removed and placed in a new 24 well. Fluorescence is detected at excitation=485 nM and emission=530 nM.

Cytotoxicity Assays

20 A cytotoxicity assay for CXCR2 compounds is conducted on 293-CXCR2 cells. Concentrations of compounds are tested for toxicity at high concentrations to determine if they may be used for further evaluation in binding and cell based assays. The protocol is as follows:

1. 293-CXCR2 cells are plated overnight at a concentration of 5000 cells
- 25 per well in complete media.
2. Dilutions of compound are made in minimal media w/0.1% BSA. Complete media is poured off and the dilutions of compound are added. Plates are incubated for 4, 24 and 48hrs. Cells are labeled with 10uM calcein AM for 15 minutes to determine cell viability. Detection method is the same as above.

30 Soft Agar Assay


10,000 SKMEL-5 cells/well are placed in a mixture of 1.2% agar and complete media with various dilutions of compound. Final concentration of agar is

0.6%. After 21 days viable cell colonies are stained with a solution of MTT (1mg/ml in PBS). Plates are then scanned to determine colony number and size. IC₅₀ is determined by comparing total area vs. compound concentration.

Compounds of this invention may exhibit a range of CXCR2 receptor binding activities from about 1 nM to about 10,000 nM.

Compounds of formula (I) may be produced by processes known to those skilled in the art in the following reaction schemes and in the preparations and examples below.

Scheme 1




10

Condensation of dibromomaleic anhydride with a substituted or unsubstituted hydrazine would give the cyclic hydrazide derivative B. Condensation of B with one equivalent of an amine (ANH₂) would give C, while the addition of a second amine (BNH₂) would give D.

15

Scheme II




Alternatively, a cyclic hydrazide with an available acidic N-H could be deprotonated with a base and alkylated by a suitable electrophile to give the corresponding N-substituted cyclic hydrazide. This intermediate could be carried further to the desired target as described in Scheme I.

5

The following examples illustrate the preparation of some of the compounds of the invention and are not to be construed as limiting the invention disclosed herein. Alternate mechanistic pathways and analogous structures will be apparent to those skilled in the art.


10

PREPARATIVE EXAMPLE 1

3-Nitrosalicylic acid (500 mg, 2.7 mmol), DCC (563 mg) and ethyl acetate (10 mL) were combined and stirred for 10 min. (R)-(-)-2-pyrrolidinemethanol (0.27 mL) was added and the resulting suspension was stirred at room temperature overnight.

15 The solid was filtered and the filtrate washed with 1N NaOH. The aqueous phase was acidified and extracted with EtOAc. The resulting organic phase was dried over anhydrous MgSO_4 , filtered and concentrated in vacuo. Purification of the residue by preparative plate chromatography (silica gel, 5% MeOH/ CH_2Cl_2 saturated with AcOH) gave the product (338 mg, 46%, $\text{MH}^+ = 267$).

20

PREPARATIVE EXAMPLE 2Step A

3-Nitrosalicylic acid (9.2 g), bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP, 23 g) and N,N-diisopropylethylamine (DIEA, 26 mL) in anhydrous CH₂Cl₂ (125 mL) were combined and stirred at 25°C for 30 min. (R) - (+)-3-pyrrolidinol (8.7 g) in CH₂Cl₂ (25 mL) was added over 25 min and the resulting suspension was stirred at room temperature overnight. The mixture was extracted with 1M NaOH (aq) and the organic phase was discarded. The aqueous phase was acidified with 1M HCl (aq), extracted with EtOAc, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to afford the crude product (7 g) which was used without further purification.

10

Step B

The crude product from Step A above was stirred with 10% Pd/C (0.7 g) in MeOH (100 mL) under a hydrogen gas atmosphere overnight. The reaction mixture was filtered through celite, the filtrate concentrated in vacuo, and the resulting residue purified by column chromatography (silica gel, 10% MeOH/CH₂Cl₂ saturated with NH₄OH) to give the product (2.5 g, 41%, MH⁺=223).

15

PREPARATIVE EXAMPLE 3-9


Following the procedures set forth in Preparative Example 2 but using the carboxylic acid, amine, and appropriate coupling agent (PyBrop) listed in the Table below, the amide product was obtained and used without further purification.

20

Prep. Ex.	Carboxylic acid	Amine	Amide Product	1. Coupling Agent 2. % Yield 3. MH ⁺
3				1. PyBrop 2. 87%, 86% 3. 181
4				1. PyBroP 2. 49% 3. 209

5		NH ₃		1. PyBroP 2. 95% 3. 153
6		-NH ₂		1. PyBroP 2. 83% 3. 167
7				1. PyBroP 2. 76% 3. 223
8				1. PyBroP 2. 59, 69 3. 207
9				1. PyBroP 2. 49, 86 3. 237

PREPARATIVE EXAMPLE 10

Step A


- 5 Following a similar procedure as in Preparative Example 1 except substituting dimethylamine (2M in THF, 33 mL) for (R)-(-)-2-pyrrolidinemethanol and 5-methylsalicylic acid (5 g) for 3-nitrosalicylic acid, the product was prepared (6.5g).

Step B

Nitric acid (0.8 mL) in H₂SO₄ was added to a cooled (-20°C) suspension of the product from Step A above (3 g) in H₂SO₄ (25 mL). The mixture was treated with 50% NaOH (aq) dropwise, extracted with CH₂Cl₂, dried over anhydrous MgSO₄,
5 filtered and concentrated in vacuo to give the product as a solid (2.1 g, 44%, MH⁺ = 225).

Step C

The product was prepared following a similar procedure as described in
10 Preparative Example 2, Step B (0.7 g, 99%, MH⁺ = 195).

PREPARATIVE EXAMPLE 11Step A

15 Following a similar procedure as in Preparative Example 2 Step A, except substituting dimethylamine for (R)-(-)-2-pyrrolidinemethanol, the product was prepared.

Step B

The product from step A above (8 g) was combined with iodine (9.7 g), silver sulfate (11.9 g), EtOH (200 mL) and water (20 mL) and stirred overnight. Filtration, concentration of the filtrate, re-dissolution in CH₂Cl₂ and washing with 1M HCl (aq) gave an organic solution which was dried over anhydrous MgSO₄, filtered and concentrated in vacuo to afford the product (7.3 g, 57%, MH⁺ = 337).

Step C

The product from Step B above (3.1 g) was combined with DMF (50 mL) and MeI (0.6 mL). NaH (60% in mineral oil, 0.4 g) was added portionwise and the mixture was stirred overnight. Concentration in vacuo afforded a residue which was diluted with CH₂Cl₂, washed with 1M NaOH (aq), dried over anhydrous MgSO₄, filtered and concentrated in vacuo. Purification through a silica gel column (EtOAc/Hex, 1:1) gave the product (1.3 g, 41%, MH⁺ = 351).

Step D

The product from Step D above (200 mg), Zn(CN)₂ (132 mg), Pd(PPh₃)₄ (130 mg) and DMF (5 mL) were heated at 80°C for 48 hrs, then cooled to room temperature and diluted with EtOAc and 2M NH₄OH. After shaking well, the organic extract was dried over anhydrous MgSO₄, filtered, concentrated in vacuo and purified by preparative plate chromatography (Silica, EtOAc/Hex, 1:1) to give the product (62 mg, 44%, MH⁺ = 250).

Step E


BBr₃ (1.3 mL, 1M in CH₂Cl₂) was added to a CH₂Cl₂ solution (5 mL) of the product from step D above (160 mg) and stirred for 30 min. The mixture was diluted with water, extracted with CH₂Cl₂, dried over anhydrous MgSO₄, filtered, and concentrated in vacuo to give the product (158 mg, MH⁺ = 236).

Step F

A mixture of the product from step E above (160 mg), platinum oxide (83%, 19 mg), and EtOH (20 mL) was stirred under hydrogen (25-40 psi) for 1.5 hr. Filtration

through celite and concentration in vacuo afforded the product (165 mg, $MH^+ = 206$).

PREPARATIVE EXAMPLE 12



5

Step A

Following a similar procedure as in Preparative Example 1 except substituting dimethylamine (2M in THF, 50 mL) for (R)-(-)-2-pyrrolidinemethanol and 4-methylsalicylic acid (15 g) for 3-nitrosalicylic acid, the product was prepared (6.3 g, 35%).

10

Step B

The product from step A above (1.5 g) was combined with iodine (2.1 g), $NaHCO_3$ (1.1 g), EtOH (40 mL) and water (10 mL) and stirred overnight. Filtration, concentration of the filtrate, re-dissolution in CH_2Cl_2 and washing with 1M HCl (aq) gave an organic solution which was dried over anhydrous $MgSO_4$, filtered and concentrated in vacuo. Purification by flash column chromatography (silica gel, 0.5-0.7% MeOH/ CH_2Cl_2) gave the product (0.3 g, 57%, $MH^+ = 306$).

15


Step C

Nitric acid (3.8 mL) in AcOH (10 mL) was added to the product from Step B above (0.8 g) and the mixture was stirred for 40 min. The mixture was diluted with water and extracted with CH_2Cl_2 , dried over anhydrous $MgSO_4$, filtered and concentrated in vacuo to give the product as a solid (0.8 g, 92%, $MH^+ = 351$).

20

Step D

A mixture of the product from step C above (800 mg), 10% Pd/C (100 mg), and EtOH/MeOH (40 mL) was stirred in a parr shaker under hydrogen (45 psi) for 1.5 hr. Filtration through celite and concentration in vacuo afforded the title product after purification by preparative plate chromatography (Silica, 10% MeOH/CH₂Cl₂, saturated with NH₄OH) to give the product (92 mg, 22%, MH⁺ = 195).

PREPARATIVE EXAMPLE 13

10


Step A

3-Nitro-1,2-phenylenediamine (10 g), sodium nitrite (5.4 g) and acetic acid (20 mL) were heated at 60°C overnight, then concentrated in vacuo, diluted with water and extracted with EtOAc. The product precipitated from the organic phase (5.7 g) as a solid and used directly in step B.

Step B

The product from Step A above (2.8 g) was stirred with 10% Pd/C (0.3 g) in MeOH (75 mL) under a hydrogen gas atmosphere overnight. The reaction mixture was filtered through celite and the filtrate concentrated in vacuo, to give the product (2.2 g, MH⁺=135).

20

PREPARATIVE EXAMPLE 145 Step A

4-Bromopyrazole-3-carboxylic acid was prepared according to known methods, see: Yu. A. M.; Andreeva, M. A.; Perevalov, V. P.; Stepanov, V. I.; Dubrovskaya, V. A.; and Seraya, V. I. in Zh. Obs. Khim. (Journal of General Chemistry of the USSR) 1982, 52, 2592, and refs cited therein.

10

Step B

To a solution of 4-bromopyrazole-3-carboxylic acid (2.0 g), available from step A, in 65 mL of anhydrous DMF was added bromotripyrrolidinophosphonium hexafluorophosphate (PyBrop, 4.60 g), dimethyl amine (10 mL, 2.0 M in THF) and diisopropylethyl amine (5.2 mL) at 25 °C. The mixture was stirred for 26 h, and concentrated under reduced pressure to an oily residue. This residue was treated with a 1.0 M NaOH aqueous solution, and extracted with ethyl acetate (4 x 50 mL). The organic extracts were combined, washed with brine, and dried with anhydrous Na₂SO₄. Removal of solvents yielded an oil, which was purified by preparative thin layer chromatography, eluting with CH₂Cl₂-MeOH (20:1), to give 1.09g of the amide product (48%, MH⁺ = 232.0).

15

20

Step C

To a solution of the amide (0.67 g), obtained from step B, in 8 mL of concentrated sulfuric acid at 0 °C was added potassium nitrate (1.16 g) in small portions. The cooling bath was removed and the mixture was heated at 110 °C for

25


6 h. After cooled to 25 °C, the mixture was poured into 80 mL of H₂O, and an additional 20 mL of H₂O was used as rinsing. The aqueous mixture was extracted with CH₂Cl₂ (100 mL x 4). The combined extracts were washed with brine (50 mL), sat. NaHCO₃ aqueous solution (50 mL), brine (50 mL), and dried over Na₂SO₄. Evaporation of solvent gave a light yellow oil, which solidified on standing. The crude product was purified by flash column chromatography, eluting with CH₂Cl₂-MeOH (1:0, 50:1 and 40:1). Removal of solvents afforded 0.521 g (65%) of the product as a solid (MH⁺ = 277.1)

10 Step D

The product (61 mg) obtained from step C was dissolved in 3 mL of THF. To this solution at – 78 °C was added dropwise along the inside wall of the flask a 1.6 M solution of n-butyl lithium in hexane. After 45 min, a solution of methyl borate (0.1 mL) in THF (1.0 mL) was added. After 1.5 h, a solution of acetic acid in THF (0.25 mL, 1:10 v/v) was added to the cold mixture. Stirring was continued for 10 min, and a 30 wt % aqueous hydrogen peroxide solution (0.1 mL) was added. An additional portion of hydrogen peroxide aqueous solution (0.05 mL) was added 20 min later. The cooling bath was removed, and the mixture was stirred at 25 °C for 36 h. The yellowish mixture was poured into 30 mL of H₂O, and the aqueous mixture was extracted with ethyl acetate (30 mL x 4). The extracts were combined, washed with brine (10 mL), 5% NaHCO₃ aqueous solution (10 mL) and brine (10 mL). The organic layer was dried with Na₂SO₄ and concentrated under reduced pressure to a residue, which was purified by preparative thin layer chromatography eluting with CH₂Cl₂-MeOH (20:1) to give the hydroxylated product (5 mg, 10%, MH⁺ = 215.3).

Step E

If one were to treat the hydroxylated product of Step D with H₂ under the conditions of 10% palladium on carbon in ethanol, one would obtain the hydroxyl-amino compound.

PREPARATIVE EXAMPLE 15Step A

- 5 Following a similar procedure used in Preparative Example 12 Step C except starting with the known compound, 4-methyl-pyrimidin-5-ol, the product of Step A could be prepared.

Step B


- 10 Following a similar oxidation procedure used in Preparative Example 14 Step A starting with the product from Step A above, the product of Step B could be prepared.

Step C

- 15 Following a similar procedure used in Preparative Example 10 Step A starting with the product from Step B above, the product of Step C could be prepared.

Step D

- 20 Following a similar procedure used in Preparative Example 11 Step F starting with the product of Step C above, the product of Step D could be prepared.

PREPARATIVE EXAMPLE 16Step A

- 5 Following a similar procedure used in Preparative Example 10 Step A starting with the known 4-hydroxynicotinic acid, the product could be prepared.


Step B

- 10 Following a similar procedure used in Preparative Example 12 Step C starting with the product from Step A above, the product of Step B could be prepared.

Step C

Following a similar procedure used in Preparative Example 11 Step F starting with product from Step C above, the amine product could be prepared.


5

PREPARATIVE EXAMPLE 17Step A

Following a similar procedure used in Preparative Example 12 Step C but
10 starting with the compound in Step A above, the nitro product could be prepared.

Step B

Stirring the nitro product from Step A above, with a suitable Pt or Pd catalyst
and EtOH under a hydrogen atmosphere (1-4 atm), the amine product could be
15 obtained.

PREPARATIVE EXAMPLE 18Step A

To a solution of 5-nitro-3-pyrazolecarboxylic acid (5.0 g, 31.83 mmol) in 160 mL of acetonitrile at room temperature was added bromotripyrrolidinophosphonium hexa-fluorophosphate (PyBrop, 14.9 g, 31.98 mmol) in small portions. A 2.0 M solution of dimethylamine in THF (40.0 mL, 80.0 mmol) was added to the mixture followed by a solution of diisopropylethylamine (14.0 mL, 80.2 mmol). After stirred for 36 h, the mixture was concentrated under reduced pressure to a residue, a mixture of solid and oil. Small volume of CH₂Cl₂ was added until all oily material was dissolved and fine colorless solid precipitated out. The solid was collected by filtration as the first crop of the product. The filtrate was concentrated to an oily residue which was treated with a mixture of CH₂Cl₂- hexanes (~1:1, v/v), and the colorless precipitation was filtered out as the second crop of the product. The combined solid product was further dried on high vacuum for several hours to afford 5.86 g (100%) of *N,N*-dimethyl 5-nitro-3-pyrazolecarboxamide as a solid (MH⁺ = 185.0).

Step B

To a solution of *N,N*-dimethyl 5-nitro-3-pyrazole amide (5.86 g, 31.83 mmol, available from step A) in 215 mL of anhydrous THF at room temperature was added solid lithium methoxide in small portions. After 45 min, iodomethane was

added dropwise. Stirring was continued for 2.5 days. The mixture was filtered through a 1.5-in silica gel pad, rinsing with large excess volume of ethyl acetate. The combined filtrate and rinsing were concentrated to a dark yellow oil, which was purified by flash column chromatography, eluting with hexanes, CH₂Cl₂, and
5 CH₂Cl₂-MeOH (50:1). Removal of solvents afforded 5.10 g (81%) of *N, N'*-dimethyl 1-methyl-5-nitro-3-pyrazole amide as a solid (MH⁺ = 199.0), contaminated by ~13% of 2-methylated isomer.

Step C

10 A solution of *N, N'*-dimethyl 1-methyl-5-nitro-3-pyrazolecarboxamide (5.10 g, 25.29 mmol), obtained from step B, in 250 mL of ethanol was degassed via house vacuum, and then refilled with nitrogen. Solid palladium (10% on activated carbon, wet with <50% water, 2.5 g) was added, the black suspension was degassed via house vacuum and then refilled with hydrogen gas supplied by a gas balloon. The
15 mixture was stirred at room temperature under a hydrogen atmosphere for 4 h, and filtered through a Celite pad, which was rinsed with ethanol. The filtrate and rinsing were combined, concentrated under reduced pressure to give 4.17 g (98%) of the amino-pyrazole product as a solid (MH⁺ = 169.0).

20 Step D

To a stirred solution of amino-pyrazole (1.0 g, 5.95 mmol), prepared in step C, in 40 mL of CH₂Cl₂ at room temperature was added benzyl chloroformate (2.7 mL, 17.97 mmol). Solid potassium carbonate (4.1 g, 29.71 mmol) was added in one portion. After 24 h, methanol (5 mL) was added to the mixture, and stirring
25 was continued for additional 2 h. Insoluble material was removed by filtration, and washed with methanol. The combined filtrate and rinsing were concentrated under reduced pressure to a thick syrup, which was separated by preparative TLC (CH₂Cl₂-MeOH = 30:1). The silica was extracted with MeOH and CH₂Cl₂, the extracts were filtered and concentrated under reduced pressure to yield 1.16 g
30 (64%) of the pyrazole benzyl carbamate as a solid (MH⁺ = 303.1).


Step E

To a stirred solution of pyrazole benzyl carbamate (1.0 g, 3.31 mmol), obtained from step D, in 100 mL of toluene at room temperature was added "Clayfen" (see note below) (3.5 g) in one portion. The dark purplish suspension
5 was heated to 70 °C and continued at 70-80 °C for 2.5 d. After cooled to room temperature, the mixture was filtered through a thin Celite pad. The solid residue and the filtration pad were rinsed with CH₂Cl₂, and filtered. The combined filtrates were concentrated to a yellowish oil, which was purified by preparative TLC (CH₂Cl₂-MeOH = 20:1). The silica was extracted with CH₂Cl₂ and methanol, the
10 extracts were filtered and concentrated under reduced pressure to give 0.822 g (72%) of the nitro-pyrazole benzyl carbamate as an oil (MH⁺ = 348.1).

Note: "Clayfen", clay-supported Iron (III) nitrate, was prepared according to literature procedures, see: Cornelis, A.; Laszlo, P. *Synthesis*, 1980, 849. To a stirred acetone solution (30 mL) at room temperature was added solid
15 Fe(NO₃)₃·9H₂O (1.8 g) in small portions. After 5 min, K-10 bentonite clay (2.4 g) was added. Stirring was continued for 30 min, and the resulting suspension was concentrated under reduced pressure (water bath temperature ≤ 30 °C). The freshly prepared material was used right away in the reaction above.

20 Step F

A solution of nitro-pyrazole benzyl carbamate (410.0 g, 1.18 mmol), available from step E, in 20 mL of ethanol was degassed via house vacuum, and refilled with nitrogen. Solid palladium (10% on activated carbon, wet with <50 % H₂O, 280.0mg) was added. The black suspension was degassed via house
25 vacuum, and refilled with hydrogen gas supplied by a gas balloon. The mixture was stirred for 20 h under a hydrogen atmosphere, and filtered through a 1-in Celite pad, rinsing with excess volume of methanol. The filtrate and rinsing were concentrated to a reddish oil, which was purified by preparative TLC (CH₂Cl₂-MeOH = 15:1). The silica was extracted with methanol, the extracts were filtered,
30 and the filtrate was concentrated under reduced pressure to an oil, which solidified while being dried on high vacuum, yielding 120.0 mg (56%) of diamino-pyrazole product (MH⁺ = 184.0).

PREPARATIVE EXAMPLE 19Step A

- 5 Nitro-pyrazole benzyl carbamate was prepared from 5-nitro-3-pyrazolecarboxylic acid according to the procedure described in Preparative Example 18.

Step B

- 10 To a solution of nitro-pyrazole benzyl carbamate (410.0 mg, 1.18 mmol), obtained from step A, in 17 mL of ethyl acetate at room temperature was added Tin (II) chloride dihydrate (1.33 g, 5.90 mmol) in one portion. The mixture was heated to 80 °C and continued for 2 h. after cooled to room temperature, a saturated NaHCO₃ aqueous solution was added dropwise to the mixture until pH
- 15 approximately 7. An additional volume of ethyl acetate (20 mL) was added, the mixture was stirred overnight, and filtered through a 1-in Celite pad. The two layers of the filtrate were separated. The organic layer was washed with brine once. The aqueous washing was combined with the aqueous layer, and extracted with ethyl acetate once. The combined organic layers were dried with Na₂SO₄, filtered and
- 20 concentrated, further dried on high vacuum, to afford 361.5 mg (97%) of amino-pyrazole benzyl carbamate as a solid (MH⁺ = 318.1).

Step C

- 25 To a stirred solution of amino-pyrazole benzyl carbamate (180.0 mg, 0.57 mmol), prepared in step B, in 11 mL of CH₂Cl₂ at -78 °C was added triethylamine


(0.32 mL, 2.30 mmol). A 1.0 M solution of methanesulfonyl chloride in CH_2Cl_2 (1.7 mL, 1.7 mmol) was added dropwise along the inside wall of the flask. The mixture was stirred for 2.5 h while the temperature of the cooling bath was increased slowly from -78°C to -25°C . A saturated NaHCO_3 aqueous solution (5 mL) was added to the mixture, and it was further diluted with 25 mL of CH_2Cl_2 . The cooling bath was removed, stirring was continued for an additional 1.5 h, and the layers were separated. The aqueous layer was extracted with CH_2Cl_2 (30 mL), and the combined organic layers were washed with a saturated NaHCO_3 aqueous solution (30 mL) and brine (30 mL). The organic layer was dried by Na_2SO_4 , and concentrated to an oil, which was purified by preparative TLC (CH_2Cl_2 -MeOH = 20:1). The silica was extracted with CH_2Cl_2 and methanol, the extracts were filtered and concentrated to a colorless oil, solidified while being dried on high vacuum, yielding 185.7 mg (83%) of the pyrazole methylsulfonamide as a solid ($\text{MH}^+ = 396.1$).

15

Step D

To a nitrogen flushed solution of pyrazole methylsulfonamide (275.0 mg, 0.70 mmol), from step C, in 10 mL of ethanol was added solid palladium (10% on activated carbon, wet with < 50% water, 550.0 mg). The suspension was degassed via house vacuum, then filled with hydrogen gas supplied by a gas balloon. The mixture was stirred for 3.5 h under a hydrogen atmosphere, and filtered through a layer of Celite. The solid residue and the filtration pad were rinsed with ethanol and ethyl acetate, the combined filtrate and rinsing were concentrated under reduced pressure to give 173.0 mg (95%) of amino-pyrazole methylsulfonamide as a solid ($\text{MH}^+ = 262.0$).

25

PREPARATIVE EXAMPLE 20Step A

- 5 Pyrazole benzyl carbamate was prepared from 5-nitro-3-pyrazolecarboxylic acid in 4 steps according to the procedure described in Preparative Example 18.

Step B

- 10 To a solution of pyrazole benzyl carbamate (115.0 mg, 0.38 mmol), prepared in step A, in 6 mL of CH₂Cl₂ at room temperature was added solid potassium carbonate in one portion. A solution of bromine was added dropwise to the stirred mixture. After 6 h, 30 mL of H₂O was added, and the mixture was extracted with CH₂Cl₂ (30 mL x 3). The combined organic extracts were washed with a 10%
 15 Na₂S₂O₃ aqueous solution (20 mL), a saturated NaHCO₃ aqueous solution (20 mL) and brine (20 mL), and dried with Na₂SO₄. Evaporation of solvent gave a slightly yellow oil, which was purified by preparative TLC (CH₂Cl₂-MeOH = 20:1). The silica was extracted with CH₂Cl₂ and methanol, the extracts were filtered and concentrated under reduced pressure to afford an oil, which was further dried on
 20 high vacuum, yielding 134.2 mg (93%) of the bromo-pyrazole benzyl carbamate (MH⁺ = 381).

Step C

- 25 Treatment of the bromo-pyrazole benzyl carbamate compound from step B with *n*-butyllithium followed by the addition of methyl borate would convert the


bromo-pyrazole benzyl carbamate to the corresponding boronic ester. Subsequent one-pot oxidation of the boronic ester with H_2O_2 aqueous solution would afford the hydroxy-pyrazole benzyl carbamate.

5 Step D

Treatment of the hydroxy-pyrazole benzyl carbamate from step C with hydrogen under the conditions of palladium (10% on activated carbon) in ethanol would afford the desired amino-hydroxy pyrazole.

10

PREPARATIVE EXAMPLE 21



Step A

To a solution of methyl 3-methoxythiophene carboxylate (2.0 g, 11.6 mmol) in 20 mL of THF at room temperature was added dropwise a 1.0 M sodium hydroxide aqueous solution (17.0 mL, 17.0 mmol). After addition, the mixture was heated to 75 °C (oil bath temperature) and continued for 18 h. The mixture was cooled to room temperature, treated with a 1.0 M hydrochloride aqueous solution until pH approximately being 2. The acidified mixture was extracted with 100 mL of CH_2Cl_2 - CH_3CN (1:1, v/v), 50 mL of CH_2Cl_2 , and 50 mL of CH_3CN . The combined organic extracts were washed with brine (30 mL), dried over Na_2SO_4 , and concentrated under reduced pressure to a solid, which was further dried on high vacuum, yielding 1.84 g (100%) of 3-methoxythiophene carboxylic acid ($\text{MH}^+ = 159.0$).

Step B

To a suspension of 3-methoxythiophene carboxylic acid (1.84 g, 11.61 mmol), from step A, in 60 mL of acetonitrile at room temperature was added
5 bromotripyrroli-dinophosphonium hexafluorophosphate (PyBrop, 5.40 g, 11.60 mmol), dimethyl amine (2.0 M in THF, 14.5 ml, 29.0 mmol) and diisopropylethyl amine (5.0 mL, 28.63 mmol) successively. After stirred for 1.5 day, the mixture was concentrated under reduced pressure to a yellow oil, which was purified by preparative TLC (CH₂Cl₂-MeOH = 40:1). The silica was extracted with CH₂Cl₂ and
10 methanol, the extracts were filtered and concentrated to an oil, which was further dried on high vacuum, yielding 4.16 g of *N, N*-dimethyl 3-methoxythiophene amide (contaminated by PyBrop impurity) (MH⁺ = 186.0).

Step C

15 To a vigorously stirred solution of thiophene amide (4.16g, prepared in step B) in 6 mL of concentrated sulfuric acid at -10 °C was added dropwise fuming nitric acid (0.6 mL, 14.28 mmol). After 1.5 h, the mixture was poured into 80 mL of a mixture of 1.0 M NaOH aqueous solution and ice (1:1, v/v). An additional 40 mL of H₂O was used to facilitate the transfer. The yellow precipitates were collected by
20 filtration, washed with H₂O twice, and dried on high vacuum, to give 1.67 g of the nitro-thiophene product. The aqueous filtrates were extracted with CH₂Cl₂ (50 mL x 3). The extracts were washed with a sat. NaHCO₃ aqueous solution (30 mL) and brine (30 mL), and dried with Na₂SO₄. Evaporation of solvent afforded a yellow oil, which was purified by preparative TLC (CH₂Cl₂-MeOH = 50:1) to give an additional
25 0.144 g of the nitro-thiophene as a solid (1.81 g total, 68% over two steps, MH⁺ = 231.0).


Step D

30 To a vigorously stirred solution of methoxy-nitro-thiophene (900.0 mg, 3.91 mmol), obtained from step C, in 55 mL of anhydrous CH₂Cl₂ at -78 °C was added dropwise along the inside wall of the flask a 1.0 M solution of boron tribromide in CH₂Cl₂ during a 15 min period. The mixture was stirred for 4 h while the temperature of the cooling bath was increased slowly from -78 °C to -10 °C, and

poured into 100 mL of a mixture of ice and H₂O (~ 1:1, v/v). Additional 30 mL of H₂O and 30 mL of CH₂Cl₂ were used to rinse the flask. The combined mixture was stirred at room temperature over night, the two layers were separated, and the aqueous layer was extracted with CH₂Cl₂ (50 mL x 3). The organic layers were combined, washed with a sat. NaHCO₃ aqueous solution (50 mL x 2) and brine (50 mL x 2), dried with Na₂SO₄, and concentrated to a yellow solid. The crude product was purified by flash column chromatography, eluting with hexanes, CH₂Cl₂-hexanes (1:1 and 2:1). Removal of solvents afforded a solid, which was further dried on high vacuum, giving 615.2 mg (73%) of the hydroxy-nitro-thiophene amide (MH⁺ = 217.0).

Step E

To a nitrogen flushed solution of hydroxy-nitro-thiophene amide (610.0 mg, 2.82 mmol), prepared in step D, in 60 mL of ethanol was added palladium hydroxide (20 wt% on activated carbon, wet with < = 50% water, 610.0 mg). The suspension was degassed via house vacuum and refilled with hydrogen gas from a gas balloon. The mixture was first stirred at room temperature under a hydrogen atmosphere for 2 h, then heated to 70 – 80 °C and continued for 20 h. Solid material was removed by filtration through a 1-in Celite pad, the filtration pad was washed with 100 mL of ethanol, and the combined filtrates were concentrated to a light yellow solid. The crude product was treated with a mixture of CH₂Cl₂-MeOH (~1:1, v/v), off-white solids precipitated out and collected by filtration as the first crop of the product (75.4 mg). The filtrate was concentrated to a solid residue, which was purified by flash column chromatography, eluting with CH₂Cl₂-EtOH (10:1 and 2:1). Removal of solvents afforded 226.8 mg of the amino-hydroxy-thiophene amide as a solid (302.2 mg total, 58%, MH⁺ = 187.0).

PREPARATIVE EXAMPLE 22Step A

- 5 2-Thiophenecarbonyl chloride (2.0mL, 18.7mmol) was dissolved in 100mL dichloromethane. After addition of diisopropylethylamine (4.1mL, 23.4mmol) and Boc-piperazine (3.66g, 19.7mmol), the mixture was stirred for 4h at room temperature. The resulting cloudy mixture was put into water (500mL) and acidified with 3N HCl to pH~1. Extraction with dichloromethane (2x100mL) and drying over sodium sulfate resulted in sufficiently pure product that was used in the next step without any further purification.
- 10 ¹H NMR (300MHz, d₆-DMSO) 1.60 (s, 9H), 3.29 (dd, 4H), 3.69 (dd, 4H), 7.23 (dd, 1H), 7.49 (d, 1H), 7.79 (d, 1H).

15 Step B

- The crude material from Step A was dissolved in trifluoroacetic acid/dichloromethane (75mL, 4/1). After stirring for 2h, the reaction mixture was put into 1N sodium hydroxide (400mL). Extraction with dichloromethane (2x100mL) and drying over sodium sulfate resulted in sufficiently pure product that was used in
- 20 Step C without any further purification.
- ¹H NMR (300MHz, d₆-DMSO) 2.81 (dd, 4H), 3.63 (dd, 4H), 7.21 (dd, 1H), 7.46 (d, 1H), 7.82 (d, 1H).

Step C

- 25 The crude material (3.50g, 17.8mmol) from Step B was dissolved in dichloromethane (100mL). After addition of diisopropylethylamine (18.7mL, 107mmol), 3-nitrosalicylic acid (3.3g, 18.0mmol), and PyBrOP (10.4g, 22.3mmol), the resulting yellow mixture was stirred over night at room temperature before being put into 1N sodium hydroxide (200mL). Extraction with dichloromethane

(2x200mL) removed all PyBrOP by-products. The aqueous phase was acidified with 3N HCl and subsequently extracted with dichloromethane (3x 100mL). The combined organic phases of the acidic extraction were dried over sodium sulfate, concentrated, and finally purified by column chromatography

5 (dichloromethane/methanol = 10/1) to yield the desired product (2.31g, 34 % over 3 steps).

¹H NMR (300MHz, d₆-DMSO) 3.30-3.90 (m, 8H), 7.10-8.20 (m, double signals due to E/Z-isomers, 6H), 10.82 (s, 1H).

10 Step D


The nitro-compound (2.3g, 6.4mmol) from Step C was dissolved in methanol (50mL) and stirred with 10% Pd/C under a hydrogen gas atmosphere over night. The reaction mixture was filtered through Celite and washed thoroughly with methanol. Finally, the filtrate was concentrated in vacuo and purified by column

15 chromatography (dichloromethane/methanol = 10/1) to yield the desired product (1.78g, 84%).

¹H NMR (300MHz, d₆-DMSO) 3.30-3.90 (m, 8H), 7.22 (m, 2H), 7.55 (d, 1H), 7.71 (d, 1H), 7.88 (d, 1H), 8.15 (d, 1H), 10.85 (bs, 1H).

20

PREPARATIVE EXAMPLE 23



Step A

Picolinic acid (3.0g, 24.3mmol) was suspended in SOCl₂ (15mL). After addition of dimethylformamide (5 drops), the reaction mixture was stirred for 4

25 hours. During this period the color changed from white to green to brown to finally dark wine-red and all solid went into solution. Evaporation of the solvent yielded the corresponding acid chloride as HCl-salt. Without any further purification, the solid was suspended in 120mL dichloromethane. After addition of diisopropylethylamine

(12.7mL, 73mmol) and Boc-piparazine (4.8g, 25.5mmol), the reaction was stirred over night at room temperature. The resulting cloudy mixture was put into water (500mL) and extracted with dichloromethane (2x100mL). Drying over sodium sulfate resulted in sufficiently pure product that was used in Step B without any further purification.

¹H NMR (300MHz, d₆-DMSO) 1.63 (s, 9H), 3.21 (dd, 4H), 3.61 (dd, 4H), 7.57 (dd, 1H), 7.63 (d, 1H), 7.98 (dd, 1H), 8.70 (d, 1H).

Step B

The crude material from Step A was dissolved in trifluoroacetic acid/dichloromethane (75mL, 4/1). After stirring for 2days, the reaction mixture was put into 1N sodium hydroxide (400mL). Extraction with dichloromethane (2x100mL) and drying over sodium sulfate resulted in sufficiently pure product that was used in Step C without any further purification.

¹H NMR (300MHz, d₆-DMSO) 2.77 (dd, 2H), 2.83 (dd, 1H), 3.38 (dd, 2H), 3.64 (dd, 1H), 7.58 (dd, 1H), 7.62 (d, 1H), 8.00 (dd, 1H), 8.67 (d, 1H).

Step C

The crude material (1.35g, 7.06mmol) from Step B was dissolved in dichloromethane (50mL). After addition of diisopropylethylamine (3.7mL, 21.2mmol), 3-nitrosalicylic acid (1.36g, 7.41mmol), and PyBrOP (3.62g, 7.77mmol), the resulting yellow mixture was stirred over night at room temperature before being put into 1N sodium hydroxide (300mL). Extraction with dichloromethane (2x100mL) removed any PyBrOP products. The aqueous phase was acidified with 3N HCl. Careful adjustment of the pH with saturated sodium carbonate solution to almost neutral crushed the desired compound out of solution. The aqueous phase was subsequently extracted with dichloromethane (3x 100mL). The combined organic layers of the neutral extraction were dried over sodium sulfate, concentrated, and finally purified by column chromatography (dichloromethane/methanol = 20/1) to yield the desired product (1.35g, 16% over 3 steps).


¹H NMR (300MHz, d₆-DMSO) 3.30-3.95 (m, 8H), 7.22 (m, 1H), 7.61 (m, 1H), 7.73 (d, 2H), 8.03 (m, 1H), 8.17 (m, 1H), 8.69 (m, 1H), 10.82 (s, 1H).

Step D

The nitro-compound (1.35g, 3.79mmol) from Step C was dissolved in methanol (60mL) and stirred with 10% Pd/C under a hydrogen gas atmosphere over night. The reaction mixture was filtered through Celite and washed thoroughly with methanol. Finally, the filtrate was concentrated in vacuo and purified by column chromatography (dichloromethane/methanol = 20/1) to yield the desired product (1.10g, 89 %).

¹H NMR (300MHz, d₆-DMSO) 3.50-3.85 (m, 8H), 6.47 (dd 1H), 6.74 (m, 2H), 7.59 (dd, 1H), 7.71 (d, 1H), 8.04 (dd, 1H), 8.68 (d, 1H).

PREPARATIVE EXAMPLE 24



Step 1

3-Nitrosalicylic acid (3.61g, 0.0197g), DCC (2.03g, 0.0099mol) and ethyl acetate (130mL) were combined in a round bottom flask and stirred for 15 min. 4-Dimethylcarbamoyl-piperazine-2-carboxylic acid ethyl ester (4.51g, 0.0197g) was added, and the reaction was stirred for 72 hours. The reaction mixture was concentrated then dissolved in dichloromethane. The organic phase was washed once with 0.1N sodium hydroxide. The aqueous phase was back extracted once with dichloromethane. The aqueous phase was acidified and wash three times with ethyl acetate. The aqueous phase was concentrated and purified by column chromatography (5% methanol/DCM).

MS: calculated: 394.15, found:395.0

¹H NMR (300 MHz, CDCl₃) 1.32 (t, 3H), 2.86 (m, 7H), 3.15 (m, 1H), 3.51 (m, 4H), 4.24 (m, 3H), 7.15 (m, 1H), 7.66 (m, 1H), 8.20 (m, 1H), 10.86 (bs, 1H).

Step 2

4-Dimethylcarbamoyl-1-(2-hydroxy-3-nitro-benzoyl)-piperazine-2-carboxylic acid ethyl ester (0.80g, 0.002mol) and methanol (50mL) were combined in a round bottom flask. The system was purged with argon. To the solution was added 5%

palladium on carbon (~100mg). The flask was purged with hydrogen and stirred overnight. The reaction was filtered through a pad of celite and washed with methanol. The material was concentrated then purified by column chromatography (6% methanol/DCM). Isolated product (0.74g, 0.002mol, 100%).

5 MS: calculated: 364.17, found:365.1

¹H NMR (300 MHz, CDCl₃) 1.27 (t, 3H), 2.85 (m, 8H), 3.18 (1H), 3.45 (m, 3H), 4.19 (m, 3H), 3.90 (m, 3H)

Step 3


10 1-(3-Amino-2-hydroxy-benzoyl)-4-dimethylcarbamoyl-piperazine-2-carboxylic acid ethyl ester (0.74g, 0.002mol) was suspended in a solution of dioxane (10mL) and water (10mL). Lithium hydroxide (0.26g, 0.0061mol) was added and the mixture stirred for two hours. The solution was acidified to pH=6 with 3N HCl then extracted with butanol. The extracts were combined, dried over sodium sulfate and
15 concentrated.

MS: calculated: 336.14, found:337.1


¹H NMR (300 MHz, CD₃OD) 2.86 (m, 7H), 3.23 (m, 3H), 3.54 (m, 3H), 6.92 (m, 2H), 7.23 (m, 1H).

20

PREPARATIVE EXAMPLE 25




The product from Preparative Example 1 was stirred with 10% Pd/C under a hydrogen gas atmosphere overnight. The reaction mixture was filtered through celite, the filtrate concentrated *in vacuo*, and the resulting residue purified by
25 column chromatography (silica gel, 4% MeOH/CH₂Cl₂ saturated with NH₄OH) to give the product (129mg, 43%, MH⁺=237).

PREPARATIVE EXAMPLE 26

In essentially the same manner as described in Preparative Example 25, the amine product above was obtained; (50% yield, $MH^+ = 300.1$).

5

PREPARATIVE EXAMPLE 27

The product is prepared according to the literature procedure (Zh.Obshch.Khim.; 24; 1954; 1216, 1220; engl. Ausg. S. 1205, 1207).



10

PREPARATIVE EXAMPLE 28-31

Following the procedure in Preparative Example 27, using the indicated commercially available hydrazines shown in the table below, the following cyclic dibromo hydrazide products could be prepared.


15

Prep Ex.	Hydrazine	Product
28		
29		
30		

PREPARATIVE EXAMPLE 32

5


The product is prepared according to the literature procedure (Farmaco Ed. Sci. IT; 32; 1977; 173-179).

PREPARATIVE EXAMPLE 33

10

Following the procedure described in the literature (J.Heterocycl.Chem.; EN; 34; 4; 1997; 1307-1314) using benzyl bromide instead of 1-chloro-propan-2-one, the product could be obtained.

15

PREPARATIVE EXAMPLE 34







Following a similar procedure as that outlined in the literature (Farmaco Ed. Sci. IT; 32; 1977; 173-179) using the product from Preparative Example 3 instead of 2-methylamino-benzenethiol, the product would be obtained.

5






PREPARATIVE EXAMPLE 35-133






Following the procedure set forth in Preparative Example 34 using the amine and dibromo intermediates from the Preparative Examples indicated, the products in the table below would be obtained.







Ex.	(Prep Ex) Amine	(Prep Ex) Dibromo	Product
35	5	27	
36	7	27	
37	6	27	
38	23	27	








39	24	27	
40	15	27	
41	11	27	
42	21	27	
43	14	27	
44	12	27	






45	19	27	
46	20	27	
47	18	27	
48	16	27	
49	3	28	






50	5	28	
51	4	28	
52	8	28	
53	7	28	
54	9	28	






55	6	28	
56	26	28	
57	23	28	
58	22	28	
59	24	28	







60	15	28	
61	16	28	
62	17	28	
63	11	28	
64	13	28	
65	21	28	







66	14	28	
67	12	28	
68	19	28	
69	14	28	
70	18	28	
71		28	






72	3	28	
73	5	28	
74	4	28	
75	8	28	
76	7	28	






77	9	28	
78	6	28	
79	26	28	
80	23	28	
81	22	28	







82	24	28	
83	15	28	
84	16	28	
85	17	28	
86	11	28	







87	13	28	
88	21	28	
89	14	28	
90	12	28	
91	19	28	
92	14	28	






93	18	28	
94	3	29	
95	5	29	
96	4	29	
97	8	29	
98	7	29	






99	9	29	
100	6	29	
101	26	29	
102	23	29	
103	22	29	






104	24	29	
105	15	29	
106	16	29	
107	17	29	
108	11	29	


109	13	29	
110	21	29	
111	14	29	
112	12	29	
113	19	29	
114	14	29	

115	18	29	
116	3	30	
117	7	30	
118	6	30	
119	11	30	
120	16	30	

121	3	31	
122	7	31	
123	6	31	
124	11	31	
125	16	31	

126	3	32	
127	7	32	
128	6	32	
129	11	32	
130	16	32	

131	3	33	
132	7	33	
133	6	33	
133.1	11	33	
133.2	16	33	

PREPARATIVE EXAMPLE 134Step A










To a solution of N-protected amino acid (1.5 g, 6.9 mmol) in CH₂Cl₂ (25 mL) at room temperature was added DIPEA (3.6 mL, 20.7 mmol), and (PyBrop) (3.4 g, 6.9 mmol) followed by MeNH₂ (6.9 mL, 13.8 mmol, 2.0 M in CH₂Cl₂). The resulting solution was stirred for 18h at room temperature (until TLC analysis deemed the reaction to be complete). The resulting mixture was washed sequentially with 10% citric acid (3 x 20 mL), sat. aq. NaHCO₃ (3 x 20 mL), and brine (3 x 20 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography eluting with CH₂Cl₂/MeOH (40:1) to afford 1.0 g (63% yield) of a solid.

Step B


To a round bottom flask charged with the N-protected amide (1.0 g, 4.35 mmol) from Step A above, was added 4N HCl/dioxane (10 mL). The mixture was stirred at room temperature for 2h. The mixture was diluted with Et₂O (20 mL) and concentrated under reduced pressure. The crude product was treated with Et₂O (2 x 20 mL) and concentrated under reduced pressure to afford 0.72 g (~100 % yield) of crude product as the HCl salt. This material was used without further purification or characterization.

PREPARATIVE EXAMPLES 135-137

Following the procedure set forth in Preparative Example 134 but using the commercially available N-protected amino acids and amines indicated, the amine hydrochloride products in the Table below were obtained.

Prep Ex.	Amino acid	Amine	Product	Yield (%)
135				68%
136				68%
137				97%

PREPARATIVE EXAMPLE 138











- 5 To a solution of 3-chlorobenzaldehyde (2.0 g, 14.2 mmol) in THF (5 mL) at 0°C was added LiN(TMS)₂ (17.0 ml, 1.0 M in THF) dropwise and the resulting solution was stirred for 20 min. EtMgBr (6.0 mL, 3.0 M in Et₂O) was added dropwise and the mixture was refluxed for 24 h. The mixture was cooled to room temperature, poured into sat. aq. NH₄Cl (50 mL), and then extracted with CH₂Cl₂ (3
- 10 x 50 volumes). The organic layers were combined and concentrated under reduced pressure. The crude residue was stirred with 3 M HCl (25 mL) for 30 min, the aqueous layer was then extracted with CH₂Cl₂ (3 x 15 mL) and the organic layers were discarded. The aqueous layer was cooled to 0 °C and treated with solid NaOH pellets until pH = 10 was obtained. The aqueous layer was extracted
- 15 with CH₂Cl₂ (3 x 15 mL) and the organic layers were combined. The organic layer was washed with brine (1 x 25 mL), dried (Na₂SO₄), and concentrated under


reduced pressure to afford 1.6 g (66% yield) of the crude amine as an oil (MH^+ 170). This material was determined to be >90% pure and was used without further purification.

5

PREPARATIVE EXAMPLES 139-142

Following the procedure set forth in Preparative Example 138 but using the commercially available aldehydes and Grignard reagents indicated, the amine products listed in the Table below were obtained.

Prep Ex.	Aldehyde	Grignard Reagent	Amine Product	1. Yield (%) 2. MH^+
139		EtMgBr		1. 73% 2. 154
140		EtMgBr		1. 55% 2. 180
141		EtMgBr		1. 80% 2. 166
142		i-PrMgBr		1. 20% 2. 150

PREPARATIVE EXAMPLE 143Step A











A mixture of 2-(trifluoroacetyl)thiophene (2 mL, 15.6 mmol), hydroxylamine hydrochloride (2.2 g, 2 eq), Diisopropylethylamine (5.5 mL, 2 eq) and MeOH (50 mL) was stirred at reflux for 48-72 hrs, then concentrated in vacuo. The residue was diluted with EtOAc, washed with 10% KH₂PO₄ and dried over Na₂SO₄ (anhydrous). Filtration and concentration afforded the desired oxime (2.9 g, 96%) which was used directly in Step B without further purification.


Step B

To a mixture of the product from Step A above in TFA (20 mL) was added Zn powder (3 g, 3 eq) portionwise over 30 min. The mixture was stirred at room temperature overnight. The solid was filtered and the mixture reduced under vacuo. Aqueous NaOH (2 M) was added and the mixture was extracted several times with CH₂Cl₂. The organic phase was dried over anhydrous Na₂SO₄, filtered and concentrated to afford the product (1.4 g, 50%).

PREPARATIVE EXAMPLES 144-148

Following the procedure set forth in Preparative Example 143 but using the commercially available ketones indicated, the amine products listed in the table below were obtained.

Prep Example	Ketone	Amine Product	1. Yield (%) 2. MH ⁺
144			1. 47% 2. 174
145			1. 71% 2. 190
146			1. 78% 2. 191
147			1. 80% 2. 190
148			1. 9% 2. 156

PREPARATIVE EXAMPLE 149Step A

To a solution of (D)-valinol (4.16 g, 40.3 mmol) in CH_2Cl_2 (60 mL) at 0 °C was added MgSO_4 (20 g) followed by dropwise addition of 3-fluorobenzaldehyde (5.0 g, 40.3 mmol). The heterogeneous solution was stirred at 0°C for 2h, was allowed to warm to room temperature and was stirred overnight (14h). The mixture was filtered and the drying agent was washed with CH_2Cl_2 (2 x 10 mL). The filtrate was concentrated under reduced pressure to afford 8.4 g (100%) of a colorless oil which was taken onto the next step without further purification.

Step B

To a solution of the imine (8.4 g, 40.2 mmol) from Step A in CH_2Cl_2 (60 mL) at room temperature was added Et_3N (6.2 mL, 44.5 mmol) followed by dropwise addition of TMSCl (5.7 mL, 44.5 mmol). The mixture was stirred for 6h at room temperature whereupon the precipitate that had formed was filtered off and washed with CH_2Cl_2 (2 x 10 mL). The combined filtrate was concentrated under reduced pressure and was taken up in Et_2O /hexane (1:1/150 mL). The precipitate was filtered off and the filtrate was concentrated under reduced pressure to afford 10.1 g (89%) of the protected imine as a red oil. This material was taken onto the next step without further purification.

Step C

To a solution of EtI (4.0 g, 25.6 mmol) in Et₂O (40 mL) at -78 °C was added t-BuLi (30.1 mL, 51.2 mmol, 1.7 M in pentane) and the mixture was stirred for 10 min. The mixture was warmed to room temperature, stirred for 1 h, and was
5 recooled to -40 °C. A solution of the imine (6.0 g, 21.4 mmol) from Step B in Et₂O (30 mL) was added dropwise via addition funnel to afford a bright orange mixture. The reaction mixture was stirred for 1.5 h at -40 °C whereupon 3M HCl (50 mL) was added and the mixture was allowed to warm to room temperature. Water (50 mL) was added and the layers were separated. The aqueous layer was extracted
10 with Et₂O (2 x 30 mL) and the organic layers were combined and discarded. The aqueous layer was cooled to 0°C and carefully treated with solid NaOH pellets until pH = 12 was obtained. The aqueous layer was extracted with Et₂O (3 x 30 mL) and the combined layers were washed with brine (1 x 30 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure to afford 4.8 g
15 (94% yield) of the amine as a red oil. This material was taken on crude to the next step without further purification.


















Step D







To a solution of amine (4.5 g, 18.8 mmol) from Step C in MeOH (80 mL) at
20 room temperature was added MeNH₂ (25 mL, 40% in water) followed by the addition of a solution of H₅IO₆ (14.0 g, 61.4 mmol) in H₂O (25 mL). The heterogenous mixture was stirred for 1.5 h (until the reaction was complete by TLC) and the precipitate was filtered off. The resulting filtrate was diluted with water (50 mL) and the mixture was extracted with Et₂O (4 x 60 mL). The combined organic
25 layers were concentrated to a volume of ~30 mL whereupon 3M HCl (75 mL) was added. The mixture was stirred overnight (12h at room temperature) whereupon the mixture was concentrated to remove the volatiles. The aqueous layer was extracted with Et₂O (3 x 40 mL) and the organic layers were discarded. The aqueous layer was cooled to 0°C and was carefully treated with solid NaOH pellets
30 until pH ~12 was reached. The aqueous layer was extracted with Et₂O (3 x 60 mL) and the combined organic layers were dried (MgSO₄). The organic layer was concentrated under reduced pressure to afford 2.8 g (97% yield) of the desired

amine as a yellow oil [MH^+ 154]. This compound was proven to be >85% pure by ^1H NMR and was used without further purification.


PREPARATIVE EXAMPLES 150-156

- 5 Following the procedure set forth in Preparative Example 149 but using the commercially available aldehydes, amino alcohols, and organolithium reagents indicated, the optically pure amine products in the Table below were obtained.

Prep Ex.	Aldehyde	Amino Alcohol	Organo lithium	Product	1. Yield (%) 2. MH^+
150					1. 54% 2. 166
151			EtLi		1. 42% 2. 142
152					1. 62% 2. 148
153			t-BuLi		1. 27% 2. 256
154			t-BuLi		1. 15% 2. 164


155			EtLi		1. 29% 2. 126
156			EtLi		1. 35% 2. 126

PREPARATIVE EXAMPLE 157




The product was prepared according to methods previously described: J.
5 Med. Chem. 1996, 39, 3319-3323.

PREPARATIVE EXAMPLE 158




The product was prepared according to methods previously described: J.
10 Med. Chem. 1996, 39, 3319-3323.

PREPARATIVE EXAMPLE 159




The product was prepared according to methods previously described:
15 Chem. Pharm. Bull. 1991, 39, 181-183.

PREPARATIVE EXAMPLE 160


The product was prepared according to methods previously described: Chem. Pharm. Bull. 1991, 39, 181-183.

5

PREPARATIVE EXAMPLE 161


The product was prepared according to methods previously described: J. Med. Chem. 1988, 31, 2176-2186.

10

PREPARATIVE EXAMPLE 162


The product was prepared according to methods previously described: J. Org. Chem. 1978, 43, 892-898.

15

PREPARATIVE EXAMPLE 163


The product was prepared according to methods previously described: J. Org. Chem. 1987, 52, 4437-4444.

20

PREPARATIVE EXAMPLE 164

The product was prepared according to methods previously described: Bull. Chem. Soc. Jpn. 1962, 35, 11-16.

5

EXAMPLE 500











Following essentially the same procedure set forth in Preparative Example 34 (outlined in the literature Farmaco Ed. Sci.; IT; 32;1977; 173-179) using the product from Preparative Example 34 and benzyl amine, one could obtain the product.











10











EXAMPLES 501-828











Following essentially the same procedure set forth in Example 500 using the products from the Preparative Examples and the prepared or commercially available amines indicated, the products in the table below could be obtained.











15











Ex.	Amine (Prep Ex)	Product of Prep.Ex	Product
501		34	
502		34	
503		34	
504		34	
505		34	











506		34	
507		34	
508		38	
509		39	
510		34	











511		35	
512		36	
513		34	
514		43	
515		34	











516		34	
517		43	
518		34	
519		34	
520		34	











521		34	
522		34	
523		41	
524		34	
525		41	











526		34	
527		34	
528		34	
529		34	
530		48	









531		37	
532		34	
533		34	
534		44	
535		34	











536		34	
537		42	
538		40	
540		34	
541		34	











542		49	
543		49	
544		64	
545		49	
546		49	











547		49	
548		49	
549		49	
550		49	
551		57	











552		49	
553		49	
554		49	
555		49	
556		57	











557		58	
558		59	
559		49	
560		50	











561		51	
562		49	
563		52	
564		49	
565		53	











566		49	
567		54	
568		66	
569		66	
570		49	











571		49	
572		49	
573		49	
574		49	
575		49	











576		49	
577		49	
578		49	
579		63	
580		63	











581		49	
582		49	
583		49	
584		49	
585		62	











586		61	
587		49	
588		49	
589		49	
590		55	











591		49	
592		49	
593		49	
594		67	
595		49	









596		49	
597		49	
598		49	
599		65	
600		60	











601		49	
602		49	
603		49	
605		72	
607		72	











608		87	
609		72	
610		72	
611		72	
612		72	











613		72	
614		72	
615		79	
616		72	
617		72	











618		72	
619		72	
620		80	
621		81	
622		82	











623		72	
624		73	
625		74	
626		72	











627		75	
628		72	
629		76	
630		72	
631		77	











632		89	
633		89	
634		72	
635		72	
636		72	











637		72	
638		72	
639		72	
640		72	
641		72	











642		72	
643		86	
644		86	
645		72	
646		72	













647		72	
648		72	
649		85	
650		84	
651		72	











652		72	
653		72	
654		78	
655		72	
656		72	











657		72	
658		90	
659		72	
660		72	
661		72	











662		72	
663		88	
664		83	
665		72	
666		72	











667		72	
668		94	
669		94	
670		109	
671		94	











672		94	
673		94	
674		94	
675		94	
676		94	
678		101	











679		94	
680		94	
681		94	
682		94	
683		102	











684		103	
685		104	
686		94	
687		95	
688		96	











689		94	
690		97	
691		94	
692		98	
693		94	











694		99	
695		111	
696		111	
697		94	
698		94	











699		94	
700		94	
701		94	
702		94	
703		94	











704		94	
705		94	
706		108	
707		108	
708		94	











709		94	
710		94	
711		94	
712		107	
713		106	











714		94	
715		94	
716		94	
717		100	
718		94	











719		94	
720		94	
721		112	
722		94	
723		94	











724		94	
725		94	
726		110	
727		105	
728		94	









729		94	
730		94	
731		116	
732		116	
733		116	









734		116	
735		116	
736		116	
737		119	
738		116	











739		116	
740		120	
741		118	
742		116	
743		116	











744		116	
745		117	
746		116	
747		116	
748		116	











749		116	
750		116	
751		126	
752		126	
753		126	











734		126	
755		126	
756		126	
757		129	











758		126	
759		126	
760		130	
761		128	











762		126	
763		126	
764		126	
765		127	
766		126	









767		126	
768		126	
769		126	
770		126	
771		131	









772		131	
773		131	
774		131	
775		131	
776		131	











777		133.1	
778		131	
779		131	
780		133.2	
781		133	











782		131	
783		131	
784		131	
785		132	
786		131	











787		131	
788		131	
789		131	
790		131	
791		121	











792		121	
793		121	
794		121	
795		121	













796	 <chem>C[C@H](N)c1ccoc1</chem>	121	 <chem>C[C@H](Nc1nc(=O)c2c(c1=O)n(C3CCCCC3)c2C4=CC=C(C=C4)C(=O)N(C)C)O</chem>
797	 <chem>C[C@H](N)c1ccccc1</chem>	124	 <chem>C[C@H](Nc1nc(=O)c2c(c1=O)n(C3CCCCC3)c2C4=CC(=CC=C4C(=O)N(C)C)[N+](=O)[O-])O</chem>
798	 <chem>CC(C)[C@H](N)C(=O)N[C@@H](C)C</chem>	121	 <chem>CC(C)[C@H](Nc1nc(=O)c2c(c1=O)n(C3CCCCC3)c2C4=CC=C(C=C4)C(=O)N(C)C)C(=O)N[C@@H](C)C</chem>
799	 <chem>CC(C)[C@H](N)C(=O)N[C@@H](C)C</chem>	121	 <chem>CC(C)[C@H](Nc1nc(=O)c2c(c1=O)n(C3CCCCC3)c2C4=CC=C(C=C4)C(=O)N(C)C)C(=O)N[C@@H](C)C</chem>







800		125	
801		123	
802		121	
803		121	
804		121	

805		122	
806		121	
807		121	
808		121	
809		121	

810		121	
811		45	
812		46	
813		47	
814		68	

815		69	
816		70	
817		91	
818		92	
819		93	


820		113	
821		114	
822		115	
823		71	
824		71	
825		71	

826		71	
827		71	
828		71	

While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A compound of the formula (I):



(I)

or pharmaceutically acceptable salts or solvates thereof wherein:

R^1 and R^{15} are the same or different and each is independently selected from the group consisting of:


- a) H,
- b) aryl,
- c) heteroaryl,
- d) alkyl,
- e) arylalkyl,
- f) heteroarylalkyl,
- g) cycloalkyl,
- h) heterocycloalkyl,
- i) cycloalkylalkyl and
- j) heterocycloalkylalkyl,

wherein said aryl, heteroaryl, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, and heterocycloalkylalkyl groups are optionally substituted with one or more substituents selected from the group consisting of:


















- a) halogen,
- b) CF_3 ,
- c) COR^{13} ,
- d) OH,
- e) $NR^{13}R^{14}$,
- f) NO_2 ,
- g) cyano,
- h) SO_2OR^{13} ,


- i) $-\text{Si}(\text{alkyl})$,
j) $-\text{Si}(\text{aryl})$
k) CO_2R^{13}
l) $\text{CONR}^{13}\text{R}^{14}$,
5 m) $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
n) SO_2R^{13} ,
o) $-\text{OR}^{13}$,
p) $-\text{O}(\text{C}=\text{O})\text{R}^{13}$,
q) $-\text{O}(\text{C}=\text{O})\text{NR}^{13}\text{R}^{14}$,
10 r) $-\text{NR}^{13}\text{COR}^{14}$, and
s) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$;

A is selected from the group consisting of:




183





185

B is selected from the group consisting of:



wherein:

R^2 is selected from the group consisting of:

- a) hydrogen,
- b) OH,
- 5 c) C(O)OH,
- d) SH,
- e) $SO_2NR^{13}R^{14}$,
- f) $NHC(O)R^{13}$,
- g) $NHSO_2NR^{13}R^{14}$,
- 10 h) $NR^{13}R^{14}$,
- i) $NHSO_2R^{13}$,
- j) $C(O)NR^{13}R^{14}$,
- k) $C(O)NHOR^{13}$,
- l) $C(O)NR^{13}OH$,
- 15 m) $OC(O)R^{13}$ and
- n) an optionally substituted heterocyclic acidic functional group,


with the proviso that if R^2 is $SO_2NR^{13}R^{14}$, then at least one of R^{13} and R^{14} must be hydrogen;

R^3 and R^4 are the same or different and each is independently selected from
20 the group consisting of:

- a) hydrogen,
- b) halogen,
- c) alkyl,
- d) alkoxy,
- 25 e) OH,
- f) CF_3 ,
- g) OCF_3 ,
- h) NO_2 ,
- i) $C(O)R^{13}$,
- 30 j) $C(O)OR^{13}$,
- k) $C(O)NR^{13}R^{14}$,
- l) $SO_{(t)}NR^{13}R^{14}$,
- m) $SO_{(t)}R^{13}$,

n) $C(O)NR^{13}OR^{14}$,

o)



p) cyano,

5

q) aryl and

r) heteroaryl,

wherein said aryl or heteroaryl group is optionally substituted with one or more R^9 group;

10 R^5 and R^6 are the same or different and each is independently selected from the group consisting of

a) hydrogen,

b) halogen,

c) alkyl,

d) alkoxy,

15

e) CF_3 ,

f) OCF_3 ,

g) NO_2 ,

h) $C(O)R^{13}$,

i) $C(O)OR^{13}$,

20

j) $C(O)NR^{13}R^{14}$,

k) $SO_{(t)}NR^{13}R^{14}$,

l) $C(O)NR^{13}OR^{14}$,

m) cyano,

n) aryl and

25

o) heteroaryl,

wherein said aryl or heteroaryl group is optionally substituted with one or more R^9 group;

R^7 and R^8 are the same or different and each is independently selected from the group consisting of

30

a) H,

- 5 b) alkyl,
 c) aryl,
 d) heteroaryl,
 e) arylalkyl,
 f) heteroarylalkyl,
 g) cycloalkyl,
 h) cycloalkylalkyl,
 i) CO_2R^{13} ,
 j) $\text{CONR}^{13}\text{R}^{14}$,
10 k) fluoroalkyl,
 l) alkynyl,
 m) alkenyl,
 n) alkynylalkyl,
 o) alkenylalkyl and
15 p) cycloalkenyl,


wherein said alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, fluoroalkyl, alkynyl, alkenyl, alkynylalkyl, alkenylalkyl, and cycloalkenyl groups are optionally substituted with one or more substituents selected from the group consisting of:

- 20 a) halogen,
 b) CF_3 ,
 c) COR^{13} ,
 d) OH,
 e) $\text{NR}^{13}\text{R}^{14}$,
25 f) NO_2 ,
 g) cyano,
 h) $\text{SO}_2\text{OR}^{13}$,
 i) $-\text{Si}(\text{alkyl})$,
 j) $-\text{Si}(\text{aryl})$,
30 k) $(\text{R}^{13})_2\text{R}^{14}\text{Si}$,
 l) CO_2R^{13} ,
 m) $\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$,
 n) $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,

- o) SO_2R^{13} ,
- p) $-\text{OR}^{13}$,
- q) $-\text{O}(\text{C}=\text{O})\text{R}^{13}$,
- r) $-\text{O}(\text{C}=\text{O})\text{NR}^{13}\text{R}^{14}$,
- s) $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$ and
- t) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$;

R^9 is selected from the group consisting of:

- a) R^{13} ,
- b) halogen,
- c) $-\text{CF}_3$,
- d) $-\text{COR}^{13}$,
- e) $-\text{OR}^{13}$,
- f) $-\text{NR}^{13}\text{R}^{14}$,
- g) $-\text{NO}_2$,
- h) cyano,
- i) $-\text{SO}_2\text{R}^{13}$,
- j) $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
- k) $-\text{NR}^{13}\text{COR}^{14}$,
- l) $-\text{CONR}^{13}\text{R}^{14}$,
- m) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$,
- n) CO_2R^{13} and
- o)



R^{10} and R^{11} are the same or different and each is independently selected

from the group consisting of:

- a) hydrogen,
- b) halogen,
- c) CF_3 ,
- d) OCF_3 ,
- e) $\text{NR}^{13}\text{R}^{14}$,
- f) $\text{NR}^{13}\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$,

- 5 g) OH,
h) C(O)OR¹³,
i) SH,
j) SO_(t)NR¹³R¹⁴,
k) SO₂R¹³,
l) NHC(O)R¹³,
m) NHSO₂NR¹³R¹⁴,
n) NHSO₂R¹³,
o) C(O)NR¹³R¹⁴,
10 p) C(O)NR¹³OR¹⁴,
q) OC(O)R¹³ and
r) cyano;

R¹² is selected from the group consisting of:

- 15 a) hydrogen,
b) OC(O)R¹³,
c) aryl,
d) heteroaryl,
e) arylalkyl,
f) cycloalkyl,
20 g) alkyl,
h) cycloalkylalkyl and
i) heteroarylalkyl,

wherein said aryl, heteroaryl, arylalkyl, cycloalkyl, alkyl, cycloalkylalkyl and heteroarylalkyl groups are optionally substituted with one or more R⁹ group;

25 R¹³ and R¹⁴ are the same or different and each is independently selected from the group consisting of:

- 30 a) H,
b) alkyl,
c) aryl,
d) heteroaryl,
e) arylalkyl,
f) heteroarylalkyl,
g) cycloalkyl,

h) cycloalkylalkyl and

i) fluoroalkyl,

wherein said alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, and fluoroalkyl groups are optionally substituted with one or more

5 substituents selected from the group consisting of:

a) alkyl,

b) aryl,

c) arylalkyl,

d) fluoroalkyl,

10 e) cycloalkyl,

f) cycloalkylalkyl,

g) heteroaryl,

h) heteroarylalkyl,

i) amino,

15 j) carbonyl and

k) halogen; or

R^{13} and R^{14} when taken together with the atoms to which they are attached form a 3 to 7 membered heterocyclic ring wherein when the ring formed is a 6 or 7 membered heterocyclic ring, said ring optionally contains one to two additional
20 heteroatoms independently selected from the group consisting of O, S and N and wherein said heterocyclic ring can be substituted with one or more substituents selected from the group consisting of:

a) alkyl,

b) aryl,

25 c) arylalkyl,

d) fluoroalkyl,

e) cycloalkyl,

f) cycloalkylalkyl,

g) heteroaryl,

30 h) heteroarylalkyl,

i) amino,

j) carbonyl and

k) halogen;

n is 0-6;

m is 1-5;


p is 0-4 and

t is 1 or 2.

5

2. The compound according to Claim 1 wherein:

A is selected from the group consisting of:



wherein,


10 R^7 is selected from the group consisting of: H, CF_3 , fluoroalkyl, alkyl and cycloalkyl;

R^8 is selected from the group consisting of H, alkyl and fluoroalkyl; and

R^9 is selected from the group consisting of H, F, Cl, Br, CF_3 , alkyl and fluoroalkyl.

3. The compound according to Claim 1 wherein:

5 B is selected from the group consisting of:



wherein

R^2 is selected from the group consisting of H, OH, $NHC(O)R^{13}$ and $NHSO_2R^{13}$;

10 R^3 is selected from the group consisting of $SO_2NR^{13}R^{14}$, NO_2 , cyano, $C(O)NR^{13}R^{14}$, SO_2R^{13} ; and $C(O)OR^{13}$;

R^4 is selected from the group consisting of H, NO_2 , halo, cyano, CH_3 and CF_3 ;

R^5 is selected from the group consisting of H, CF_3 , NO_2 , halo and cyano;

15 R^6 is selected from the group consisting of H, alkyl and CF_3 .

R^{10} and R^{11} are the same or different and each is independently selected from the group consisting of:

- a) hydrogen,
- b) halogen,
- 20 c) CF_3 ,
- d) OCF_3 ,
- e) $NR^{13}R^{14}$,
- f) $NR^{13}C(O)NR^{13}R^{14}$,
- g) OH,

- h) $C(O)OR^{13}$,
i) SH,
j) $SO_{(t)}NR^{13}R^{14}$,
k) SO_2R^{13} ,
l) $NHC(O)R^{13}$,
m) $NHSO_2NR^{13}R^{14}$,
n) $NHSO_2R^{13}$,
o) $C(O)NR^{13}R^{14}$,
p) $C(O)NR^{13}OR^{14}$,
q) $OC(O)R^{13}$,
r) COR^{13} ,
s) OR^{13} and
t) cyano;

R^{12} is selected from the group consisting of hydrogen and $C(O)OR^{13}$;
 R^{13} and R^{14} are the same or different and each is independently selected from the group consisting of methyl, ethyl and isopropyl; or
 R^{13} and R^{14} when taken together with the atoms to which they are attached form a 3 to 7 membered heterocyclic ring wherein when the ring formed is a 6 or 7 membered heterocyclic ring, said ring optionally contains one to two additional heteroatoms independently selected from the group consisting of O, S and N and wherein said heterocyclic ring can be substituted with one or more substituents selected from the group consisting of:

- a) alkyl,
b) aryl,
c) arylalkyl,
d) fluoroalkyl,
e) cycloalkyl,
f) cycloalkylalkyl,
g) heteroaryl,
h) heteroarylalkyl,
i) amino,
j) carbonyl and
k) halogen.


4. The compound according to Claim 1 wherein:

R^1 and R^{15} are the same or different and each is individually selected from the group consisting of H, methyl, aryl and cyclohexyl.

5

5. The compound according to Claim 1 wherein

A is selected from the group consisting of:



wherein,

10 R^7 is selected from the group consisting of H, CF_3 , CF_2CH_3 , methyl, ethyl, isopropyl, cyclopropyl and t-butyl;


R^8 is H and

R^9 is selected from the group consisting of H, F, Cl, Br, CF_3 , alkyl, and fluoroalkyl.

15

6. The compound according to Claim 1 wherein:

B is



wherein:

20 R^2 is selected from the group consisting of H, OH, $NHC(O)R^{13}$ and $NHSO_2R^{13}$;

R^3 is selected from the group consisting of $SO_2NR^{13}R^{14}$, NO_2 , cyano, $C(O)NR^{13}R^{14}$, SO_2R^{13} ; and $C(O)OR^{13}$;

R^4 is selected from the group consisting of H, NO_2 , halo, cyano, CH_3 and CF_3 ;

R^5 is selected from the group consisting of H, CF_3 , NO_2 , halo and cyano;


R^6 is selected from the group consisting of H, alkyl and CF_3 ; and

5 R^{13} and R^{14} are the same or different and each is independently selected from the group consisting of methyl, ethyl and isopropyl; or


R^{13} and R^{14} when taken together with the atoms to which they are attached form a 3 to 7 membered heterocyclic ring wherein when the ring formed is a 6 or 7 membered heterocyclic ring, said ring optionally contains one to two additional
 10 heteroatoms independently selected from the group consisting of O, S and N and wherein said heterocyclic ring can be substituted with one or more substituents selected from the group consisting of:

- a) alkyl,
- b) aryl,
- 15 c) arylalkyl,
- d) fluoroalkyl,
- e) cycloalkyl,
- f) cycloalkylalkyl,
- g) heteroaryl,
- 20 h) heteroarylalkyl,
- i) amino,
- j) carbonyl and
- k) halogen.

25 7. The compound according to Claim 1 wherein A is selected from the group consisting of:



and B is:



wherein:

5 R² is selected from the group consisting of H, OH, NHC(O)R¹³ and NHSO₂R¹³;

R³ is selected from the group consisting of SO₂NR¹³R¹⁴, C(O)NR¹³R¹⁴, SO₂R¹³, NO₂ and cyano;

R⁴ is selected from the group consisting of H, NO₂, CF₃, CH₃, halo and cyano;

10 R⁵ is selected from the group consisting of H, halo, NO₂, cyano and CF₃;

R⁶ is selected from the group consisting of H, CF₃ and alkyl;

R⁷ is selected from the group consisting of: H, CF₃, CF₂CH₃, methyl, ethyl, isopropyl, cyclopropyl and t-butyl;

15 R⁸ is H;


R⁹ is selected from the group consisting of H, F, Cl, Br, CF₃, alkyl, and fluoroalkyl; and

R¹³ and R¹⁴ are each independently selected from the group consisting of methyl and ethyl.


20

8. The compound according to Claim 1 wherein A is selected from the group consisting of:

198



and B is



wherein,









5









 R^2 is $-\text{OH}$; R^3 is $\text{CONR}^{13}\text{R}^{14}$; R^4 is selected from the group consisting of H, CH_3 , halo and CF_3 ; R^5 is selected from the group consisting of H and cyano; R^6 is selected from the group consisting of H, CH_3 and CF_3 ; and









10

 R^{13} and R^{14} are each methyl.











9. The compound according to Claim 1 wherein said compound is selected from the group consisting of:















10. The compound according to Claim 1, wherein said compound is selected from the group consisting of:
















and



5

11. The compound according to Claim 1 wherein said compound is selected from the group consisting of:





12. A pharmaceutical composition comprising a compound
 5 of Claim 1 and a pharmaceutically acceptable carrier therefor.

13. A use of a compound of Claim 1 for the manufacture of a medicament
 for treating a chemokine-mediated disease in a patient in need of such treatment,
 wherein the chemokine binds to a CXCR2 and/or CXCR1 receptor in said patient.
 10

14. A use of a compound of Claim 1 for the manufacture of a medicament
 for treating a chemokine-mediated disease in a patient in need of such treatment,
 wherein the chemokine binds to a CXC receptor in said patient.

15. The use of Claim 13 wherein the chemokine mediated disease is
 selected from the group consisting of psoriasis, atopic dermatitis, asthma, chronic
 obstructive pulmonary disease, adult respiratory disease, arthritis, inflammatory
 bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock,
 gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion
 20 injury, glomerulonephritis or thrombosis, Alzheimer's disease, graft vs. host

reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis and cerebral and cardiac ischemia.

16. A use for the manufacture of a medicament for treating cancer in a
5 patient in need of such.

17. The use of Claim 16 wherein the treatment further comprises the use of at least one known anti-cancer agent and/or radiation therapy.

10 18. The use of Claim 17, wherein said anti-cancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids (including synthetic analogs), and synthetics.

15 19. A use for the manufacture of a medicament for inhibiting angiogenesis in a patient in need of such inhibition.

20. The use of Claim 19 wherein the treatment further comprises the use of at least one known anti-angiogenesis compound.

20

21. The use of Claim 20 wherein said anti-angiogenesis compound is selected from the group consisting of Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet
25 Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, VEGF receptor kinase inhibitors, docetaxel and paclitaxel.

22. A use for the manufacture of a medicament for treating a disease in a
30 patient in need of such treatment, said disease selected from the group consisting of gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi's sarcoma associated virus and atherosclerosis.

23. The use of Claim 13 wherein said chemokine mediated disease is an angiogenic ocular disease.

5 24. The use of Claim 23 wherein said angiogenic ocular disease is selected from the group consisting of ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization.

10 25. The use of Claim 16 wherein the tumor type is melanoma, gastric carcinoma or non-small cell lung carcinoma.

26. The use of Claim 25 wherein the treatment further comprises the use of at least one known anti-cancer agent and/or radiation therapy.

15 27. The use of Claim 26, wherein the anti-cancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids (including synthetic analogs), and synthetics.

20 28. The use of Claim 27 wherein the anti-angiogenic agent is selected from the group consisting of Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566,
25 CGS27023A, VEGF receptor kinase inhibitors, docetaxel and paclitaxel.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/00299

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D237/22 C07D409/12 C07D405/12 C07D417/12 C07D403/12
 A61K31/501 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 376 079 A (NISSAN CHEM. IND.) 4 July 1990 (1990-07-04) page 1; claims	1,13
A	EP 0 275 997 A (NISSAN CHEM. IND.) 27 July 1988 (1988-07-27) page 1; example 8; table 5	1,13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

9 May 2003

Date of mailing of the international search report

22/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/00299

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 376079	A	04-07-1990	JP 2256668 A	17-10-1990
			CA 2004538 A1	20-06-1990
			EP 0376079 A1	04-07-1990
			US 5011839 A	30-04-1991
EP 275997	A	27-07-1988	AT 83773 T	15-01-1993
			AU 597141 B2	24-05-1990
			AU 1039688 A	21-07-1988
			CA 1324792 A1	30-11-1993
			DD 287497 A5	28-02-1991
			DE 3876813 D1	04-02-1993
			DE 3876813 T4	11-05-1995
			EP 0275997 A1	27-07-1988
			HU 46313 A2	28-10-1988
			JP 2550631 B2	06-11-1996
			JP 63301870 A	08-12-1988
			SU 1584750 A3	07-08-1990
			US 4978665 A	18-12-1990
			ZA 8800309 A	01-07-1988